Identification of risks for drug-related problems by Kaufmann, Carole
IDENTIFICATION OF RISKS FOR  
DRUG-RELATED PROBLEMS 
 
 
Inauguraldissertation 
zur Erlangung der Würde eines Doktors der Philosophie 
vorgelegt  
der Philosophisch-Naturwissenschaftlichen Fakultät  
der Universität Basel 
 
von  
Carole Patrizia Kaufmann 
aus Basel (BS), Ballwil (LU) 
 
 
Basel 2015 
 
 
Originaldokument gespeichert auf dem Dokumentenserver der Universität Basel 
edoc.unibas.ch 
 
Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät  
auf Auftrag von 
 
 
Prof. Dr. Kurt E. Hersberger 
Dr. Markus L. Lampert 
Prof. Dr. David Schwappach 
 
 
 
 
 
Basel, den 13.10.2015 
 
 
 
 
 
 
Prof. Dr. Jörg Schibler 
Dekan 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To my family 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Acknowledgements 
The presented work was conducted at the Pharmaceutical Care Research Group, Department 
of Pharmaceutical Sciences, at the University of Basel under the supervision of Prof. Dr. Kurt 
Hersberger and Dr. Markus Lampert. I am deeply thankful for the support of the following 
persons. This research project would not have been possible without them. 
First, I would like to express my deepest gratitude to Dr. Markus Lampert who supervised this 
thesis with great commitment and enthusiasm. Thank you Markus, for your valuable scientific 
and non-scientific support and your trust and for sharing my “unrealistically optimistic” ideas. 
I own you a huge part of my personal development be that in the area of research, education 
or clinical pharmacy.  
Many important thanks go to Prof. Dr. Kurt Hersberger for his watching over this thesis. Thank 
you Kurt for your valuable ideas and inputs. I am admiring your talent to create such a pleasant 
and familiar working atmosphere in our team. I enjoyed being a PhD-student in the PCRG-
group, it was great to learn from your pharmaceutical expertise and to take part in all the 
national and international scientific exchanges and all the great team events. 
Further thank goes to Prof. Dr. David Schwappach for accepting the co-reference and his 
interest in my thesis as well as to Prof. Dr. Matthias Hamburger for acting as chair at the 
defence. 
I would also like to thank the Swiss Association of Public Health Administration and Hospital 
Pharmacists (GSASA) for their financial support of this thesis. 
Many thousand thanks to all my dear colleagues from the Pharmaceutical Care Research 
Group (PCRG) for the great working atmosphere. Most cordial thanks to Kurt’s Gang: Fabienne 
Böni, Markus Messerli, Samuel Allemann, Karen Maes, Corinna Metaxas and Dominik Stämpfli 
for being a second little family to me during the last years. Thank you for all the great working- 
and non-working hours we spent together, for all your unconditional support and care.  
Furthermore, I would like to thank the whole team of the Basel Pharmacoepidemiology Unit 
for the great collaboration and all the good times at the ESCP conferences, the afterworks and 
in the Chalet. Thank you Julia and Saskia for the 24/7 availability in our technical and 
motivational help chat and for your valuable friendship. Thank you Marlene for your 
motivation during the last months. 
Many thanks to the whole team of the hospital pharmacy of the Kantonsspital Baselland, 
Bruderholz for the great three years. Special thanks to Maya von Moos, Andrea Studer, 
Charlotte Rapp and Seraina Mengiardi-Nemec for being such lovely team members. 
Thank you to the expert panel for participating in project B and to all the people from the 
Kantonsspital Baselland, Standort Bruderholz and Liestal, who enabled the conduction of the 
patient interviews.  
A huge thank you to the whole team of the hospital pharmacy at the University Hospital of 
Basel for the warm welcoming last year. Many cordial thanks go to Prof. Dr. Christoph Meier 
for being such a motivating and supportive head. I am looking forward to continuing my work 
in your team. A special thank goes to my colleagues from the division of clinical pharmacy. 
Thank you Delia, Sibylle, Patrick, Andy, Julian, Balbina, Stephan, Samantha and Daphne for 
your great support that gave me a lot of relief in the last months.  
Many thanks to my master students Regina Tremp, Dominik Stämpfli, Nadine Mory and Timon 
Stolz for their excellent work. 
Many thanks to Ben Basger and April Stockfleet for the English proof reading, Michael Mittag 
for his support in analysis and statistics, Dr. Katja Suter for her advices on how to conduct 
systematic literature reviews as well as Balbina Preston and Christina Ernstberger for the 
participation in the patient interviews.  
Finally, my deepest gratitude goes to my amazing family and closest friends. Thank you, to my 
parents for your unconditional support in every minute of my life. It would have been 
impossible to finish this thesis without your care during the last weeks. Many thanks to Muriel, 
my favourite little sister. Thank you to my friends, Alina, Marina, Judith, Stephanie, Simone, 
Isabella, Mark and Melanie for being always at my side and care for me, even when my life 
was completely taken up with work.  
 
Table of Contents 
Acknowledgements ................................................................................................................... 5 
Abbreviations ............................................................................................................................. 8 
Summary .................................................................................................................................. 10 
General Introduction ............................................................................................................... 14 
Drug-related problems ......................................................................................................... 14 
Inappropriate prescribing ..................................................................................................... 17 
Clinical Pharmacy .................................................................................................................. 22 
Risk Assessment .................................................................................................................... 26 
Rational and approach ............................................................................................................ 29 
PROJECT A: Inappropriate prescribing .................................................................................... 32 
Introduction .......................................................................................................................... 33 
PROJECT A1 
Inappropriate prescribing: A systematic overview of assessment tools .............................. 34 
PROJECT B: Assessment of patients at risk for drug-related problems ................................. 63 
Introduction .......................................................................................................................... 64 
PROJECT B1  
Determination of risk factors for drug-related problems: a multidisciplinary triangulation 
process .................................................................................................................................. 70 
PROJECT B2  
The Drug Associated Risk Tool - DART  A new instrument to screen patients at risk for 
drug-related problems .......................................................................................................... 88 
B3  
How to detect patients at risk for drug-related problems: a structured overview of 
assessment tools................................................................................................................. 106 
General discussion and conclusions ...................................................................................... 116 
Limitations .......................................................................................................................... 124 
Conclusions ......................................................................................................................... 126 
Outlook ............................................................................................................................... 127 
References.............................................................................................................................. 128 
Annex ..................................................................................................................................... 138 
Curriculum vitae .................................................................................................................... 164
 Abbreviations  
PhD Thesis Carole Kaufmann 8 
Abbreviations 
A  Ambulatory patients 
ADE  Adverse Drug Event 
ADR  Adverse Drug Reaction 
BMQ  Beliefs about medicines questionnaire 
CP  Clinical Pharmacy 
CRF  Case Report Form 
DART  Drug Associated Risk Tool 
Dp  Delphi technique 
DRP  Drug-related Problem 
eGFR  estimated glomerular filtration rate 
El  Elderly 
Ex  Expert panel 
GSASA  Swiss Association of public health administration and hospital pharmacists 
H  Hospitalized patients 
IP  Inappropriate prescribing 
IQR  Interquartile range 
Lit  Literature search 
MAI  Medication Appropriateness Index 
ME  Medication Error 
MESH  Medical Subheading 
MMAS  Morisky Medication Adherence Scale 
MMSE  Mini Mental State Examination 
MMT  Micro Mental Test 
MR  Medication Review 
 Abbreviations  
PhD Thesis Carole Kaufmann 9 
MRP  Medication Related Problem 
n.a.  Not applicable 
NGT  Nominal Group Technique 
NRS  Nutritional Risk Screening 
n.s.  Not specified 
NSAID  Non-steroidal anti-inflammatory drugs 
PIM  Potentially inappropriate medication 
RD  RAND Appropriateness method 
RF  Risk factor 
ϕ  Phi-coefficient 
χ2  Chi-square 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Summary  
PhD Thesis Carole Kaufmann 10 
Summary 
Drug-related problems (DRPs) are defined as an event or circumstance involving drug therapy 
that actually or potentially interferes with desired health outcomes. The term DRP is an 
‘umbrella’ term that includes medication errors (MEs), adverse drug events (ADEs) and 
adverse drug reactions (ADRs). A ME is any preventable event that may cause or lead to 
inappropriate medication use or patient harm while the medication is in the control of the 
healthcare professional, patient or consumer. An ADE is an injury - whether or not causally 
related to the use of a drug - and an ADR is any response to a drug which is noxious and 
unintended, and which occurs at doses normally used in humans for prophylaxis, diagnosis or 
therapy of diseases, or for the modification of physiological functions. DRPs are common and 
occur at every stage of care. They are responsible for patient harm and cause substantial 
additional healthcare cost. A considerable amount of DRPs is judged by the literature as 
preventable.  
Inappropriate prescribing (IP) constitutes a major risk for the occurrence of DRPs and is highly 
prevalent, especially in the elderly, where polymorbidity and polypharmacy are often part of 
everyday life. An appropriate prescription of medication should “maximize efficacy and safety, 
minimise cost, and respect patient‘s preferences”.  
Clinical pharmacy (CP) is an area of pharmacy with the aim of developing and promoting the 
appropriate, safe and cost-effective use of therapeutic products. A clinical pharmacist 
assumes responsibility for managing medication therapy in direct patient care. CP services for 
in-patients have a beneficial effect on patient safety by reducing medication errors and ADEs; 
they are effective in improving the patients knowledge about drug therapy and their 
adherence. The involvement of a clinical pharmacist who provides clinical pharmacy services 
such as patient counselling and medication review has proved to be a successful approach to 
support the physician in reducing IP.  
Numerous tools for the assessment of IP have been published and can be a valuable aid during 
the physicians prescribing process or a medication review of a pharmacist. Until today a 
comprehensive and structured overview of existing tools has not been available. 
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In most European countries, staffing restrictions are a major barrier for the development of 
CP services. At the same time, an impressively growing drug market and an increasing number 
of elderly patients with complex polypharmacy demand the need for clinical pharmacists. To 
meet the requirements of optimising patient’s drug therapies while at the same time dealing 
with limited capacity, pharmacists are forced to target their clinical activities to those patients 
who are most likely to benefit from them ─ that is, to focus on those who are at the highest 
risk of experiencing DRPs. 
This thesis aimed to create a comprehensive overview on available tools for the assessment 
of IP. In a second part, a risk assessment tool for the occurrence of DRPs should be developed 
to enable pharmacists to target their clinical activities on high-risk patients. 
In project A, a systematic literature search on PUBMED resulted in 46 tools for the assessment 
of IP, all different in terms of IP content, structure and length, targeted health care settings 
(hospital care, ambulatory care, long-term care) and patient groups (elderly, all age), 
development method (literature review, expert panels and/or consensus techniques) and 
extent of validation. By outlining the characteristics of each tool in a highly structured manner, 
we created a survey, which did not identify a single ideal tool but who revealed their strengths 
and weaknesses what may help readers to choose one, either for research purposes or for use 
in daily practice, according to the situation in which it is intended to be applied.  
In project B we developed a risk assessment tool, to support pharmacists in focussing their 
clinical activities. The development of such a risk assessment tool required in a first step an 
identification of risk factors (RFs). As RFs for the occurrence of DRPs are numerous, they 
cannot be fully covered by an IP assessment tool.  
In project B1 we therefore intended to get a broader impression on possible RFs for the 
occurrence of DRPs. We conducted a multidisciplinary expert panel, using the nominal group 
technique (NGT) and a qualitative analysis to gather risk factors for DRPs. The literature was 
searched for additional risk factors. Gathered factors from the literature search and the NGT 
were assembled and validated in a two-round Delphi questionnaire. This approach resulted in 
a final list of 27 RFs judged by the experts to be “important” or “rather important” for the 
occurrence of DRPs. 
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In project B2 we developed the Drug Associated Risk Tool (DART) out of the RFs that we 
identified in project B1. We conducted a prospective validation study with 164 patients and 
validated the DART concerning feasibility, acceptability and reliability of patients answers. 
Feasibility and acceptability of the DART were satisfactory. Compared to other risk assessment 
tools, summarized in a separate overview B3, the DART reached a high overall specificity of 
95% and a slightly low overall sensitivity of 58%.  
 
From the results and experiences of this thesis the following conclusions could be drawn: 
 Inappropriate prescribing (IP) is a major risk for the occurrence of DRPs. The avoidance of 
IP should not only be the task of the physician but shared between different healthcare 
providers in order to guarantee the most appropriate therapy. Tools for the assessment 
of IP can provide a useful aid to evaluate the appropriateness of a therapy, during a 
medication review, or during the process of prescribing itself.  
 Inappropriate prescribing assessment tools are numerous. They show a large variety in 
structure, degree of comprehensiveness and extend of validation. By providing an 
overview of published assessment tools, this thesis may assist healthcare providers to 
choose a tool, either for research purposes or for use in daily practice, according to the 
situation in which it is intended to be applied.  
 The Drug Associated Risk Tool (DART) is a promising approach for clinical pharmacists to 
assess patients at risk for the development of DRPs and thereby target their clinical 
pharmacy activities to those patients who benefit the most thereof. 
 The DART is based on a combination of a systematic literature search, with the 
professional experience and knowledge of a multidisciplinary expert panel, which enabled 
the comprehensive finding of risk factors for DRPs representing the real-life situation in 
the Swiss healthcare setting. 
 A first technical validation of the DART was successful and supported the concept of a 
patient self-assessment. Compared to similar self-assessment tools, the DART has 
comparable complexity and comprehensiveness, has an appealing design and shows a 
satisfactory validation concerning feasibility, acceptability and reliability of patients’ 
answers.  
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We saw a lower sensitivity of the DART compared to similar risk self-assessments. We 
proposed potential issues that might have affected the sensitivity of our tool: The 
understandability of the questions, the accuracy of medical histories and medical data and the 
reliability of patient answers. A rephrasing of the statements with very low sensitivity values 
with the aim of improving the understanding of the question followed by a second validation 
with a most accurate medication list is recommended. A validation with clinical outcomes is 
crucial to prove the concept of our risk assessment.  
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General Introduction 
Drug-related problems 
“Medical advance offers the hope of bringing benefits to patients but also has the potential to 
do harm if not used appropriately. Knowing when and how to treat patients is particularly 
important in the prescribing of drugs as populations’ age and multi-morbidity becomes more 
prevalent” Duerden, 2013 [1].  
In the late 1950s, the German pharmaceutical company Chemie-Gruenenthal launched 
thalidomide as a new sedative and tranquilizer. The new drug was very effective and 
discovered to also be effective for the treatment of morning sickness in pregnant women. 
Thalidomide became one of the world’s largest selling drugs, advertised as “completely safe” 
[2]. Two years after its’ release, patients started to develop peripheral neuropathy after taking 
the drug. Shortly thereafter, thalidomide was connected with an epidemic of severe birth 
defects in children whose mothers had taken the drug during pregnancy. The prescription of 
thalidomide was named as the largest man-made medical disaster in history causing damage 
to over 10000 children [3]. Intensive discussions on the preventability of this tragedy were 
responsible for an increasing awareness of drug-related harm and led to efforts for the 
improvement of drug safety.  
Researchers began to evaluate the occurrence of drug-related problems (DRPs) in primary and 
secondary care. DRPs are defined as an event or circumstance involving drug therapy that 
actually or potentially interferes with desired health outcomes [4]. The term DRP is an 
“umbrella” term that includes medication errors (MEs), adverse drug events (ADEs) and 
adverse drug reactions (ADRs). Table 1 shows current definitions used in this thesis.  
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Table 1: Definition and terms associated with DRPs 
 
Miller at al. [8] prospectively analysed 7014 hospital admissions between 1969 and 1972. Data 
were collected in seven hospitals in the USA, Canada and Israel and revealed that ADRs were 
the main cause of admission or at least strongly influenced the admission of 260 (3.7%) 
patients. With the similar aim of describing the frequency and pattern of drug-related 
morbidity resulting in hospital admission ,Nelson and Talbot [9], reviewed 452 newly 
hospitalized patients charts. They concluded that 16.2% of the patients were hospitalised due 
to DRPs. The authors judged 50% of drug-related admissions as definitely preventable. A study 
from the UK of Pirmohamed et al. (2004) screened 18820 hospital admissions, with 1225 
(6.5%) of the admissions related to the occurrence of an ADR [10]. However, issues with the 
definition of medication safety terms cast doubt on a statement that more than 70% of the 
ADRs could have been potentially or definitely avoided. This was because ADRs, which form a 
subset of adverse drug events (ADEs), have been defined as non-preventable (cf. table 1). 
Despite numerous research projects demonstrating the problems of medication-related 
injury, international interest in patient safety remained limited. A turning point in the subject 
came in the year 1999, when the US Institute of Medicine issued their report “To err is 
human”[11]. This report was based upon an analysis of multiple studies by a variety of 
organizations, and showed that medical errors cause up to 98,000 deaths and more than 1 
million injuries each year. This publication had a big impact on the recognition of medication 
management problems.  
 
MEDICATION ERROR  
(ME) 
Any preventable event that may cause or lead to inappropriate 
medication use or patient harm while the medication is in the control of 
the healthcare professional, patient or consumer [5] 
ADVERSE DRUG EVENT  
(ADE) 
An injury—whether or not causally related to the use of a drug [6] 
ADVERSE DRUG REACTION  
(ADR) 
Any response to a drug which is noxious and unintended, and which 
occurs at doses normally used in humans for prophylaxis, diagnosis or 
therapy of diseases, or for the modification of physiological functions. 
An ADR is defined as non-preventable [7]. 
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Differences between definitions of medication safety terms in the literature has led to 
frequent confusion between researchers. The following example illustrates the complexity of 
the classification: A patient receiving oral anticoagulation therapy develops a gastrointestinal 
bleed. If the use of oral anticoagulation in this patient was appropriate (correct dosage, 
indication and appropriate monitoring), this may be classified as an ADR, a non-preventable 
event due to an inherent risk of gastrointestinal bleeding with oral anticoagulation. If the 
bleeding occurred because of a wrong usage of the drug (e.g. overdosage, no monitoring, 
contraindication present), classification would consist of an ADE, as it would have been 
preventable. The often incorrect use of DRP associated terms complicates a proper 
comparison of the results from research articles. The illustration in figure 1 should facilitate 
the understanding of the different subterms.  
Figure 1: Illustration of DRPs and associated terms (modified from Otero et al. [12]) 
Today, many studies have shown that DRPs occur at every stage of care. Five to 15% of all 
hospital admissions are drug-related and largely preventable [13-15]. The occurrence of DRPs 
continues during hospitalization. In a systematic review covering the decade from 1991 to 
2001, Krähenbühl-Melcher et al [16] showed that approximately 6% of all hospitalized patients 
experienced an ADE and in 3% of the affected patients, the adverse event was fatal. Five to 
10% of all drug prescriptions or drug applications were erroneous. Schlienger et al. [17] 
investigated in a prospective study the incidence of ADEs on the medical ward of a Swiss 
harm 
No harm 
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university hospital. ADEs occurred in about 15% of all patients. During hospital stay, the 
medication of a patient undergoes many changes. Almost every patient receives new 
medicines added to his existing treatment, with others being stopped [18]. Approximately 
60% of drugs change at the time of discharge with half of the medications on the discharge 
prescription being new to the patient [19]. Paulino et al. [18] published a study where 112 
community pharmacies from all over Europe took part. The pharmacists interviewed 445 
patients with a prescription after hospital discharge and found DRPs in 277 (64%) of these 
patients. According to a recent Swiss study, 27% of the discharge prescriptions contained at 
least one DRP and 34% of the prescriptions showed qualitative deficiencies like illegible drug 
names, missing/unclear drug form or dosage [20]. In a Swiss thesis from 2001, patients during 
home-interviews, after being discharged, reported handling difficulties (8%), side effects 
(21,6%), and gaps in drug supply (24%) and the researcher discovered potentially harmful 
drug-drug interactions in 22.4% of the cases [19]. Williams et al [21] confirmed, that with a 
better management of seamless care, including medication management, 59% of all 
unplanned readmissions would be avoidable. 
Patients experiencing an ADE showed an almost doubled risk of death [22]. Besides human 
suffering, DRPs cause substantial additional cost and a prolonged length of hospital stay. Bates 
et al. [23] stated that an ADE resulted in 2.2 additional days of hospital stay and additional 
costs of $3244. Many other researchers support Bates findings, clearly indicating the 
increasing economic burden and the prolonged length of hospital stay, regardless of whether 
the studies focused on DRPs, ADEs or ADRs [22, 24-28]. 
 
Inappropriate prescribing 
” The appropriate prescription of medication should maximize efficacy and safety, minimise 
cost, and respect patient‘s preferences” Barber 1995 [29]. 
A major risk for the occurrence of drug-related problems (DRPs) constitutes inappropriate 
prescribing (IP). DRPs resulting in actual and potential ADEs occur throughout the entire 
medication process, half of these at the stage of prescription (49%) [30]. Choosing the most 
appropriate medication for each patient in order to achieve desired therapeutic outcomes is 
a challenge for healthcare professionals in their daily practice [31]. Trained to prescribe in a 
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rational way, they consider evidence-based guidelines for the most effective treatments with 
the best benefit-risk ratios. This of course is an essential part of prescribing. However, when 
focusing on appropriate prescribing instead of rational prescribing, patient’s preferences 
should be incorporated in every decision[29] even when, from a rational point of view, an 
appropriate prescription might not always be the most effective one. This also implies the 
omission of drugs, which may otherwise have been indicated according to current guidelines, 
with the aim of reducing a patient’s drug burden and promote drug adherence. 
According to Spinewine [32] inappropriate prescribing (IP) can be grouped in three 
subcategories [33, 34]:  
 Underprescribing – the omission of a medication that is needed (no therapy prescribed 
for a given indication) 
 Overprescribing – the prescription of a medication that is clinically not indicated (resulting 
in unnecessary therapy). 
 Misprescribing – the incorrect prescription of an indicated medication ─ for example, a 
wrong dosage or duration of therapy; a drug-drug, drug-food or drug-disease interaction, 
or the selection of a drug where better alternatives (better benefit-risk ratio / better cost-
effectiveness ratio) would be preferable.  
Inappropriate prescribing (IP) is highly prevalent, especially in the elderly, where 
polymorbidity and polypharmacy are part of everyday life. In a retrospective Irish population 
study in 2010 [35], Cahir et al. screened 338,801 electronic patient charts and found the 
prevalence of IP in primary care to be 36%. A retrospective cross-sectional study of 2707 
elderly receiving home care services across 11 European countries documented the 
prevalence of potentially inappropriate prescribing [36]. By using validated explicit criteria like 
the Beers criteria [37] and McLeods criteria [38] they identified 19.8% of patients with at least 
one inappropriate medication. These European findings are comparable with data from the 
USA [39, 40], where the prevalence of IP among community-dwelling elderly has been 
reported to be 21% [39]. A recent Swiss study revealed similar results by screening claims data 
from the largest health insurance in the country, which revealed that 21% of community 
dwelling elderly received at least one potentially inappropriate drug [41]. 
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The act of prescribing is mainly the task of the physician. Different approaches have been 
evaluated in order to support physicians in reducing IP, as summarized by Spinewine et al. 
[32]: 
 Educational approaches including printed information material and interactive courses 
may improve prescribers’ knowledge about appropriate prescribing and improve 
prescribing behaviour. The more personalised, interactive and multidisciplinary the 
approaches are the more effective they are. Educational interventions have to be 
repeated frequently in order to be sustainable. The covering of the broad topic of 
appropriate prescribing is time consuming. Therefore, educational interventions are often 
restricted to certain diseases or special groups of drugs. 
 Computerized decision support systems (CDSS) and/or computerized physician order 
entry (CPOE) can serve as an electronic support at the time of prescribing. If the system 
is linked to clinical data, it is possible to cover all categories of IP. The implementation is 
time-consuming, as all relevant data and information need to be entered and regularly 
updated. Generally, the integration of a new system to existing working processes might 
be challenging. The system needs to be easy to use, with avoidance of high volumes of 
warnings, because the physician tends to override them.  
 A comprehensive assessment of drug therapy by an interdisciplinary team, usually 
composed of physicians (often geriatricians), nurses, pharmacists and other specialized 
health-care professionals is an expensive and complex approach. Nevertheless, if 
successful, patients’ therapy benefits from the different competences of each healthcare 
professional, potentially resulting in a very comprehensive medication review (MR). 
 Involvement of a clinical pharmacist who provides clinical pharmacy services such as 
patient counselling and medication review has been proved to reduce IP. The clinical 
pharmacist needs training in conducting medication reviews. Some expertise in geriatric 
pharmacotherapy might be a benefit because the occurrence of IP increases in the elderly. 
A close collaboration with the prescriber and full access to the clinical record of the 
patient are necessary for a successful implementation.  
A combination of the mentioned interventions has proved to be more effective than one single 
approach. 
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A medication review (MR) is “an evaluation of patient‘s medicines with the aim of managing 
the risk and optimizing the outcome of medicine therapy by detecting, solving and preventing 
DRPs” [42]. It can be provided by physicians, pharmacists and nurses, in primary and 
secondary care. A recently published study summarized the evidence of MRs [43]. The author 
concluded that there is evidence that MR improves outcomes of prescribing such as reduced 
polypharmacy and an appropriate choice of medicines. However, there is still no evidence for 
the reduction of “harder outcomes” such as hospitalization and mortality [44].  
There are numerous tools for the assessment and evaluation of the appropriateness of 
prescribing. Usually developed by literature review, expert panels and/or consensus 
techniques, they can serve as an aid for physicians, pharmacists and other healthcare 
providers during their medication review. Tools differ in terms of structure, length and 
content, use in different healthcare settings and in particular patient groups. They can be 
grouped roughly into implicit (judgement- based) and explicit (criterion-based) tools, and tools 
showing a combination of both approaches. Chang and Chan [45] compared different criteria 
for the assessment of IP in the elderly and concluded that not all of the criteria considered the 
same drugs as inappropriate. This also depended upon the availability of the drugs in different 
countries.  
The consideration of whether to choose explicit or implicit criteria can be important, as they 
may provide different findings. In a US study, Steinman et al. [46], evaluated the drug 
prescribing quality by using both - the explicit Beers Criteria and the implicit MAI in the same 
cohort of patients. The two tools provided substantially different results (cf. figure 2). Based 
on his observations, Steinman concluded that, because using a single tool may fail to capture 
the overall quality of a patient’s medication regimen, it would seem prudent to consider 
employing multiple tools to capture the range of quality problems that may be present in 
medication prescribing [46]. A tool using both approaches (explicit AND implicit) can serve as 
an alternative to the use of multiple tools.  
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Figure 2: Concordance of drug-level measures of prescribing quality for 1582 drugs. Circles are proportional to 
the number of drug quality problems identified. Numbers represent the number of drugs within each category. 
The area of the box outside the circles represents the number of drugs without any prescribing problem [46]. 
Reprinted by permission from Wolters Kluwer Health, Inc. 
 
Despite a wide selection of different tools, their use in the daily clinical setting is very limited. 
Most tools are very comprehensive and appear more suitable for research purpose. Numerous 
pages of guidelines make it impossible to assess a patient’s drug therapy in a short amount of 
time. Further, validation in terms of demonstrating a significant relation between 
inappropriate drug use and adverse drug outcomes is often missing.  
Validation is the confirmation, through the provision of objective evidence, that the 
requirements for a specific intended use or application have been fulfilled [47]. During the 
development process of a tool some technical aspects of validation should be considered like 
the appropriateness, acceptability, feasibility, interpretability and reliability of a tool [48]. 
After a successful technical validation, it is important to validate a tool concerning clinical 
outcomes. An assessment tool for IP might fulfil all aspects of a technical validation but its 
application remains questionable if the tool has no proven effect on adverse outcomes (e.g. 
reduction of rehospitalisation, morbidity, mortality).  
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A comprehensive and structured overview of existing tools for the assessment of IP has not 
been available. The aim of project A of this thesis was to conduct a systematic literature review 
to provide an overview of published assessment tools. This approach may help healthcare 
professionals to choose the most suitable tool, either for research purposes or for daily 
practice use, according to its intended application. 
 
Clinical Pharmacy  
The profession of pharmacy has experienced significant development over the past 50 years. 
While the traditional role of the ancient “apothecary” was characterized by the manufacturing 
and selling of drugs, his importance waned when the development of drugs became more and 
more the task of the pharmaceutical industry. Downgraded from the important role of the 
drug manufacturer to the profession of a simple drug dispenser, pharmacists saw themselves 
needing to redefine their professional activities. Clinical pharmacy (CP) had its beginning in 
the early 1960s in the USA when pharmacists began to change their focus from the product 
to the patient [49].  
The Swiss Association of public health administration and hospital pharmacists (GSASA) 
defined clinical pharmacy as an area of pharmacy with the aim of developing and promoting 
the appropriate, safe and cost-effective use of therapeutic products. In the hospital setting, 
clinical pharmacy includes direct patient oriented pharmaceutical activities, implemented on 
patient care wards in collaboration with other healthcare professionals [50]. According to the 
definition of the American College of Clinical Pharmacy, a clinical pharmacist assumes 
responsibility for managing medication therapy in direct patient care. He is an expert in the 
therapeutic use of medication and provides drug therapy evaluations and recommendations 
to the patient and healthcare providers. Thereby he practices independently and/or as a 
consultant in collaboration with other healthcare professionals [51]. This definition 
encompasses appropriate and inappropriate prescribing. CP is not necessarily linked to the 
hospital environment. It can be provided by community pharmacies to nursing homes, in 
home-based care services and in other settings where drugs are prescribed and used. It should 
be emphasized that CP is not synonymous with hospital pharmacy. While the basic work of a 
hospital pharmacist includes activities such as logistic supply, quality control and 
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manufacturing of drugs, the focus of attention of the clinical pharmacist moves from a focus 
on the drug to that of the single patient. 
Clinical pharmacy services are multifaceted and occur at every point of care. A selection of 
core activities of the clinical pharmacists are [50]:  
 Provision of counselling activity and drug information for healthcare professionals. 
 Participation on ward rounds in an interdisciplinary team of healthcare professionals in 
order to improve a patients’ drug therapy.  
 Performing medication reviews, defined as a “structured, critical examinations of 
patient’s medicines with the objective of reaching an agreement with the patient about 
treatment, optimising the impact of medicines, minimising the number of medication 
related problems and reducing waste” [52]. 
 Medication reconciliation: The process of identifying the most accurate list of all 
medications that the patient is taking including name, dosage, frequency, and route, by 
comparing the medical record to an external list of medications obtained from a patient, 
hospital, or other provider [53]. 
 Education of healthcare professionals; enhancing drug therapy knowledge and improving 
prescribing behaviour. 
 Educating patients; improving patients’ knowledge and awareness of their drug therapy. 
 Monitoring and improving patients’ adherence. 
 Assurance of seamless care. 
 Provision of therapeutic drug monitoring for high-risk drugs. 
There are more and more studies available evidencing the positive clinical, humanistic and 
economic benefit of CP services provided to hospitalized patients. A systematic review 
covering the time from 1985 to 2005 [54] and a large observational study from 2005 [55] 
support the use of clinical pharmacists. They both concluded that CP services for in-patients 
have a beneficial effect on patient safety by reducing medication errors and ADEs; they are 
effective in improving the patients’ knowledge about drug therapy and their adherence, and 
the use of inappropriate medicines decreases. A comprehensive systematic review by 
Chisholm et al [56] examined the effect of pharmacist-provided direct patient care. After 
having screened over 56,000 titles and abstracts, there were 298 full texts included in this 
review. The results provided clear evidence concerning the favourable effect of pharmacists 
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on patient care. Patients treated by a care team including a pharmacist showed significantly 
better therapeutic and safety outcomes compared to those without pharmacists in their care 
teams. Favourable effects were demonstrated on blood pressure measurements, 
International Normalized Ratio values, glycated haemoglobin (HbA1c) - and lipid levels. 
Mortality, readmissions, inpatient length of stay and emergency department visits decreased, 
as well as MEs and ADEs. Pharmacists’ effects on humanistic outcomes such as medication 
adherence, patient satisfaction and knowledge showed variable results. Their benefit was less 
obvious, but the evidence remained positive with the most favourable data concerning the 
enhancement of patient knowledge about medication and disease states. CP also proved to 
be cost-effective [57]. An economic review [58], calculated a mean cost-benefit ratio of 1:4,68. 
In a more recent study [59], data assessed over a one-year period in 2012 confirmed former 
findings; pharmacist interventions in hospitals provided substantial cost-avoidance to the 
healthcare payer. 
While nowadays the clinical pharmacy is well implemented in the USA, this specialized field of 
pharmacy is only in the beginning stages in most European countries. Only the UK and Ireland 
have developed CP services to a significant extent. In 71% of all US hospitals, pharmacists are 
integrated to such an extent, that they review and approve almost all medication prescriptions 
before the administration of the first dose, except those arising in emergencies. However, the 
level to which European hospital pharmacists document their clinical activities is low. Because 
of this, collected data from Europe do not provide detailed information about the involvement 
of clinical pharmacists. Statistics collected on the number of pharmacists per hospital and their 
activities on the ward identify notable differences across Europe, such that we appear far from 
providing CP services as the USA [60].  
Staffing restrictions are a major barrier for the development of CP services. In most countries, 
the economic pressure on healthcare providers is pronounced. A European survey performed 
by the European Association of Hospital Pharmacists (EAHP) [60] revealed important 
differences between countries in allocation of human resources to hospital pharmacies. The 
number of pharmacists (full time equivalents) per 100 bed ranged from 0.24 in Bosnia-
Herzegovina to 4.35 in the United Kingdom (cf. figure 3). These data suggest that the greater 
the number of employed pharmacists, the greater the time spent on clinical services, such as 
daily patient ward visits. 
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Figure 3: Percentage of pharmacies with either daily visits on the wards by pharmacists or having pharmacists 
working at least 50% of their time on the ward. Total may be >100% when both services are provided [60]. 
Reprinted by permission from BMJ Publishing Group Ltd. 
 
To provide CP services effectively and efficiently, pharmacists must have adequate skills and 
knowledge. Education and training at both pre- and postgraduate levels is essential. The 
number of specific programs for clinical pharmacists is continuously growing, but in many 
European countries there is still a lack of well-trained specialists in the field to meet increased 
needs. In Switzerland, most CP services take place in the hospital setting and the number of 
activities varies greatly from one hospital to another. Figure 4 shows the regional differences 
in the provision of CP services. A recent online survey among all hospital pharmacies affiliated 
with the national professional society revealed that 69 persons (22%) out of 307 employed 
hospital pharmacists had a formal specialisation in CP. Twenty-eight of these have both a 
hospital and clinical pharmacy specialisation and 146 had a masters degree in pharmacy [61]. 
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Figure 4: Extend of clinical pharmacy services in the various language areas (French, German, Italian); FTE: Full 
time equivalent [62] 
 
Risk Assessment 
“The goal of risk identification is to ensure that the patients who will most likely benefit from 
these services are identified, thereby enhancing the cost effectiveness of these interventions“ 
Coleman 2003 [63].  
An impressively growing drug market and an increasing number of elderly patients with 
complex polypharmacy demand the need for clinical pharmacists. The dilemma of increased 
pharmaceutical needs versus the limited resources available requires good management of 
CP services. To meet the requirements of optimising patient’s drug therapies while at the 
same time dealing with limited capacity, pharmacists are forced to target their clinical 
activities to those patients who are most likely to benefit from them ─ that is, to focus on 
those who are at the highest risk of experiencing DRPs. 
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The identification of patients who are mostly at high risk of DRPs would allow clinical 
pharmacists to be more target-oriented. This does not mean that clinical pharmacy should 
neglect standard care. It can rather be seen as a reallocation of available resources when 
additional capacities are not available. Clinical pharmacists could provide individualised care 
for patients who were at higher risk, and reduce their care in patients who were at lower risk 
(cf. figure 5). 
 
Figure 5: The identification of patients at risk allows clinical pharmacists to target clinical pharmacy activities. 
 
The identification of patients at risk requires the identification of risk factors (RFs) for the 
development of DRPs. Literature serves as a valuable source for the collection of RFs. 
However, published studies appear very heterogeneous depending on the study design (e.g. 
prospective, retrospective), the study setting (e.g. ambulatory care, nursing homes or 
hospitals), the study population (e.g. all patients, elderly, patients with particular chronic 
diseases), the outcomes upon which the authors focused (e.g. DRPs, ADEs, ADRs, hospital 
admission) and the way data were collected (e.g. by pharmacist, physician, nurse). Although a 
comparison of findings is difficult, a literature search can provide an overview of the current 
research and of RFs judged as the most important ones. However, data from the literature 
might not fully reflect the current problems of practicing healthcare providers, especially 
when the information comes from another country with a completely different healthcare 
 
Patients at low risk 
Patients at high risk 
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system. The consultation of an expert panel, consisting of actively practicing healthcare 
professionals may reveal valuable RFs, seen in daily practice but not mentioned in most 
research projects.  
Once RFs are identified, patient showing these factors then need to be screened in a reliable 
way by using as little CP resources as possible. The approach of risk assessments has proved 
successful in other areas of care. One of the best-known risk assessments is the Nutritional 
Risk Screening (NRS) [64], designed in 1999. This identifies patients who are likely to benefit 
from nutritional support, which will then provide an improved clinical outcome, i.e., they are 
at-risk of nutrition-related complications and/or other indices of worsened outcome if 
untreated. The screening characterizes patients by scoring the components ‘undernutrition’ 
and ‘severity of disease’ in four categories (absent, mild, moderate and severe). The patient 
can have a score of 0–3 for each component, a total score of 0–6, and any patient with a total 
score of three or higher is considered at risk for undernutrition and is believed to benefit from 
nutritional support. The NRS has been well implemented in primary and secondary care. A 
validation study has proved the association of a high NRS score with negative clinical outcomes 
like increased mortality, higher rate of complications and longer lengths of hospital stay [65].  
A similar approach may also be promising in the area of medication safety. An easy-to-use risk 
assessment tool appears to be a reliable way to screen patients at risk of DRPs who may 
benefit from targeted clinical pharmacy services. 
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Rational and approach 
The percentage of old and very old persons in the community increases constantly [66]. 
Advances in medical science and technology have converted formerly fatal acute diseases into 
survivable events, often resulting in chronic health conditions [67]. Chronic health conditions 
often require polypharmacy and the growing pharmaceutical industry supports intensive 
therapies by continuously developing new innovative drugs. Polypharmacy is a well-known 
risk factors for the occurrence of DRPs [16]. The adverse outcomes of DRPs have been the 
subject of many research projects. The different understanding of DRPs, the various and 
sometimes incorrect use of the term DRP and its associated concepts, and the heterogeneity 
of study designs and outcome measures has complicated a detailed comparison of existing 
data. However, evidence clearly indicates that DRPs lead to patient harm and increasing 
healthcare costs. A large number of DRPs are known to be preventable with targeted 
interventions [13]. Inappropriate prescribing (IP), as a major contributing risk for DRPs, is a 
prevalent cause for the occurrence of adverse outcomes. The association of IP with patient 
harm and an economic burden has been proven by various studies [32].  
The employment of clinical pharmacists has shown to be efficient in reducing IP and the 
occurrence of DRPs and proved to be cost-effective [54, 55]. The clinical pharmacist with his 
focus on the patient’s therapy rather than on the drug itself may be the healthcare 
professional of choice to improve medication safety in primary and secondary care. Restricted 
resources and time limits activities of pharmacists. Targeting CP activities is crucial to prevent 
the development of DRPs in the most effective way.  
 
This thesis aims to identify RFs for the development of DRPs. We approached this aim in two 
major steps: 
In project A we conducted a systematic literature review to provide a comprehensive 
overview of assessment tools for inappropriate prescribing (IP). A structured mapping was 
intended to facilitate orientation and assist healthcare professionals in comparing existing 
tools and choosing the most suitable one for their work and research. To our knowledge, no 
similar overview has been published so far. 
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Inappropriate prescribing is a major risk for DRPs. However, an IP assessment tool cannot fully 
cover the broad range of risk factors (RFs). There is a high need for a screening tool that takes 
the full range of RFs into consideration. In project B1 we intended to create a basis for such a 
tool and therefore get a broad impression on possible RFs for the occurrence of DRPs. The 
strategy of using a combination of current evidence from the literature with the professional 
experience of healthcare providers should serve as comprehensive approach to identify a list 
of important RFs for DRPs that accurately reflect the reality of daily practise. Out of this list, a 
screening tool should be developed for the detection of patients at risk (project B2). This risk 
assessment should allow pharmacists to target their clinical activities where they are needed 
most. The tool should be validated regarding feasibility, acceptability and the reliability of 
patients answers by calculating sensitivity and specificity.  
Parallel to project B1 and B2, we aimed to search the literature for already existing tools. This 
approach may provide ideas for the development of our risk assessment tool. Results are 
shown in the overview B3. A synopsis of the rational is listed below and serves as an overview 
of the thesis. 
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A condensed overview of the projects and aims of the thesis 
 
A INAPPROPRIATE PRESCRIBING 
PROJECT A: INAPPROPRIATE PRESCRIBING: A SYSTEMATIC OVERVIEW OF PUBLISHED 
ASSESSMENT TOOLS 
The aim of this project was to create a comprehensive and structured overview 
of existing tools for the assessment of inappropriate prescribing. 
 
B ASSESSMENT OF PATIENTS AT RISK FOR THE DEVELOPMENT OF DRUG-RELATED PROBLEMS 
PROJECT B1: DETERMINATION OF RISK FACTORS FOR DRUG-RELATED PROBLEMS: A 
MULTIDISCIPLINARY TRIANGULATION PROCESS 
With project B1 we aimed to assess risk factors for the occurrence of DRPs with 
the intention to use them as a basis for the further development of a screening 
tool to identify patients at risk for DRPs. 
 
PROJECT B2: THE DRUG ASSOCIATED RISK TOOL – DART: A NEW INSTRUMENT TO SCREEN 
PATIENTS AT RISK FOR DRUG-RELATED PROBLEMS 
The aim of this study was to create a self-assessment questionnaire out of the 
identified risk factors from project B1 and to validate the questionnaire 
regarding feasibility, acceptability, and the reliability of the patients’ answers. 
 
B3: HOW TO DETECT PATIENTS AT RISK FOR DRUG-RELATED PROBLEMS: AN 
OVERVIEW ON EXISTING SCREENING TOOLS 
In this part we aimed to create a structured overview on existing tools to screen 
for patients at risk for DRPs.  
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Introduction 
Inappropriate prescribing (IP) is prevalent in primary and secondary care and has a clearly 
demonstrated association with negative outcomes. The consequences of IP are the 
occurrence of ADEs and increased morbidity, mortality and healthcare utilization [32, 68-70]. 
It is not surprising that IP is responsible for an increased economic burden. Cahir et al. [35] 
estimated the total expenditure due to IP to be 45.6 million euros for one year. Many 
screening tools have been developed to detect and measure IP and assist prescribers with 
prescribing guidelines for their daily clinical practice. The first screening tool, developed in 
1991 in the USA, was the Beers criteria [71]. These explicit criteria consisted of a list of drugs 
to avoid in elderly nursing home residents. They have been regularly updated, the most recent 
in 2014 [37, 72, 73]. In 1992, Hanlon et al. developed the Medication Appropriateness Index 
(MAI) [74] in the USA. In contrast to the explicit criteria of Beers, the MAI was an implicit tool, 
which demonstrated a different approach by providing ten questions to the prescriber in order 
to assess the appropriateness of a patients’ therapy. Since then researchers have developed 
numerous new assessment tools, which have often been derived from existing tools and 
adapted in structure and content. The growing range of tools complicates the orientation in 
this field of research.  
In project A of this thesis, we aimed to provide a comprehensive and structured overview of 
all existing IP assessment tools, what – to our knowledge – has not been done so far. By 
conducting a systematic literature review, we intended to find all published assessment tools. 
A structured mapping was designed to highlight their characteristics and allow a comparison 
of the structure and the content of these tools. The compilation might help healthcare 
professionals choose the appropriate tool or combination of tools for their own purposes and 
raise awareness of advantages and limitations of IP assessment tools. Thus, this overview 
might contribute to improving their prescribing behaviour in daily practice. 
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Abstract 
Background: Criteria to assess the appropriateness of prescriptions might serve as a helpful 
guideline during professional training and in daily practice, with the aim to improve a patient’s 
pharmacotherapy. 
Objective: To create a comprehensive and structured overview of existing tools to assess 
inappropriate prescribing. 
Method: Systematic literature search in Pubmed (1991–2013). The following properties of the 
tools were extracted and mapped in a structured way: approach (explicit, implicit), 
development method (consensus technique, expert panel, literature based), focused patient 
group, healthcare setting, and covered aspects of inappropriate prescribing. 
Results: The literature search resulted in 46 tools to assess inappropriate prescribing. Twenty-
eight (61%) of 46 tools were explicit, 8 (17%) were implicit and 10 (22%) used a mixed 
approach. Thirty-six (78%) tools named older people as target patients and 10 (22%) tools did 
not specify the target age group. Four (8.5%) tools were designed to detect inappropriate 
prescribing in hospitalised patients, 9 (19.5%) focused on patients in ambulatory care and 6 
(13%) were developed for use in long-term care. Twenty-seven (59%) tools did not specify the 
healthcare setting. Consensus methods were applied in the development of 19 tools (41%), 
the others were based on either simple expert panels (13; 28%) or on a literature search (11; 
24%). For three tools (7%) the development method was not described. 
Conclusion: This overview reveals the characteristics of 46 assessment tools and can serve as 
a summary to assist readers in choosing a tool, either for research purposes or for daily 
practice use. 
 
Keywords: Drug-related problems, inappropriate prescribing, assessment tool, drug safety 
 
 PROJECT A: Inappropriate prescribing  
PhD Thesis Carole Kaufmann 36 
Introduction 
The appropriate prescription of medication should “maximize efficacy and safety, minimize 
cost, and respect patient‘s preferences”[29]. Choosing the most appropriate medication for 
each patient in order to achieve desired therapeutic outcomes is a challenge for healthcare 
professionals in their daily practice [31]. Criteria to assess the appropriateness of prescriptions 
and to improve a patient’s pharmacotherapy might serve as a helpful guideline during 
professional training and on the job on a daily basis. In recent years, with inappropriate 
prescribing becoming an important public health concern, different tools to assess 
inappropriate prescribing have been developed and published. These tools show major 
differences in structure and content. They can be grouped roughly into implicit (judgement- 
based) and explicit (criterion-based) tools, and tools showing a combination of both 
approaches. 
Explicit tools are usually developed from published reviews, expert opinions, and consensus 
techniques. These criterion-based tools are mostly drug-oriented and/or disease-oriented and 
can be applied with little or no clinical judgement [32]. Explicit criteria are generally used as 
rigid standards and neither address individual differences among patients, nor the complexity 
and appropriateness of entire medication regimens [31]. They need to be updated regularly 
to ensure their conclusiveness. Furthermore, each country has specific guidelines, standards 
and approved medications, which makes a country specific adaption of explicit criteria 
necessary. The advantages are the lower cost of application and a higher degree of fairness in 
ensuring a more equal care [75]. Implicit tools are judgement-based, patient-specific, and 
consider the patient’s entire medication regimen [31]. Implicit criteria often depend on the 
user’s knowledge, experience and attitude. They can also take into account patients’ 
preferences. However, they may be time-consuming and can have low reliability [32]. 
The combination of both explicit and implicit criteria enables to link the advantages of each 
approach. Explicit guidelines serve as background to supply user’s clinical judgement of 
patient’s medication and implicit questions provide a patient specific approach with mostly a 
small number of items. 
Creating a valid tool for the assessment of the appropriateness of a medication requires 
adequate evidence. In areas of healthcare where higher levels of evidence (e.g. controlled 
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trials) are missing, consensus techniques are useful methods to develop an evidence base. 
These group facilitation techniques were developed to explore the level of consensus among 
a group of experts, whereby consensus is reached by summarizing many opinions into a single, 
agreed-upon, refined opinion [76]. Combining expert opinions with evidence from the 
literature seems to be a good approach to create a valid, useful tool. Types of consensus 
techniques are the RAND appropriateness method, the Delphi technique and the nominal 
group technique (NGT). The RAND combines current scientific evidence with the opinion of 
elected experts. Panelists rate, meet for discussion and then re-rate issues of interest. The 
Delphi technique consists of multiple questionnaire rounds with feedback to the panelists 
between rounds and uses evidence-based literature as a basis but omits expert meetings. The 
NGT is widely used to generate and prioritize ideas but usually has no initial review of the 
current scientific literature [76]. 
Several publications summarize and compare selected existing tools to assess the 
appropriateness of prescribing [31, 45, 77-81], but a comprehensive overview is still missing. 
The existing publications either focus on specific patient groups or only show just a small 
comparison of the most popular tools. Therefore, the objective of this study is to provide a 
systematic literature search to create a comprehensive and structured overview of all existing 
tools. A mapping will highlight their characteristics and will allow a comparison of the structure 
and the content of these tools. 
Methods 
Pubmed database search included the time period from January 1, 1991, to March 19, 2013. 
The search strategy contained the following terms and combinations: Inappropriate 
Prescribing [MESH] OR inappropriate prescribing [All Fields] OR inappropriate 
prescribing/classification [All Fields] OR inappropriate prescribing/economics [All Fields] OR 
inappropriate prescribing/ethics [All Fields] OR inappropriate prescribing/ history [All Fields] 
OR inappropriate prescribing/methods [All Fields] OR inappropriate prescribing/mortality [All 
Fields] OR inappropriate prescribing/nursing [All Fields] OR inappropriate 
prescribing/psychology [All Fields] OR inappropriate prescribing/trends [All Fields] OR 
inappropriate prescribing/utilization [All Fields] OR inappropriate prescribings [All Fields] OR 
inappropriate prescription [All Fields] OR inappropriate prescriptions [All Fields]. The MESH 
term “Inappropriate prescribing” was introduced only in 2011. Prior to this, “inappropriate 
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prescribing” was included in the broadly defined MESH term “Drug therapy”. We limited the 
search to studies in adults. Articles must have been published in English or German. The 
database search was completed with a manual search from the reference lists of included 
articles. The reviewer (RT) assessed publications for eligibility by title and abstract screening. 
Each article showing uncertainty regarding inclusion or exclusion criteria was discussed 
between three of the authors (RT, CK, ML). 
Inclusion and exclusion criteria 
We included articles describing tools or computerised decision support systems to assess 
inappropriate prescribing, updated versions of already published tools and adaptations of an 
already published tool if its further development was based on new expert consensus. We 
defined the following exclusion criteria: Tools restricted to specific therapeutic classes (e.g., 
benzodiazepines, antibiotics, etc.), or specific diseases, tools targeted to children, adaption of 
already published tools to computerised decision support systems, medication review 
techniques which did not use a tool, educational interventions to improve prescribing 
practice, validation studies of previously published tools, and general guidelines or 
recommendations to assess inappropriate prescribing. 
Mapping of the tools 
We grouped the tools in three main domains (explicit, implicit and mixed tools). In every 
domain, tools were ordered according the strength of evidence of their development method 
(consensus technique, expert panel, literature based). To highlight the characteristics of the 
tools we listed all properties in a structured way. We categorised inappropriate prescribing 
according to Spinewine [32] into underprescribing, overprescribing and misprescribing and 
defined these terms as follows [33, 34]:  
Underprescribing: The omission of a medication that is needed (no therapy for a given 
indication) 
Overprescribing: The prescription of a medication that is clinically not indicated (unnecessary 
therapy) 
Misprescribing: The incorrect prescription of an indicated medication. 
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We further divided misprescribing in: 
 Drug choice: Better alternatives are available (better risk-benefit ratio or better cost-
effectiveness) 
 Dosage: Prescribed dose too low, too high, or not correctly adapted to patient 
characteristics (e.g. renal function, body weight.) 
 Duration of therapy: Duration of therapy too long or too short 
 Duplication: Inappropriate prescription of drugs of the same pharmacological class 
 Drug-Disease, Drug-Drug, Drug-Food Interactions: Combination of a drug with another 
drug, with food or with a medical condition with a potential or manifest negative impact 
on the therapeutic outcome 
We listed the focused patient group (elderly, all age), and healthcare setting (hospital care, 
ambulatory care, long-term care). In addition, we added adherence, cost-effectiveness and 
whether the tool suggested alternative therapies to the inappropriate ones. The aspect of 
adherence represents, to a certain extent, the patients’ preferences. Intentional non-
adherence reflects patients’ unwillingness to take their medication, mostly caused by a 
therapy regimen which does not respect their preferences and, according to Barber’s 
definition [29] is therefore inappropriate. 
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Results 
A total of 716 articles was identified through database search. The numbers of included and 
excluded articles at each stage are displayed in a flowchart (cf. Fig. A-1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A-1: Flowchart of the literature search 
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In the end, 46 publications met the inclusion criteria and described 46 different tools. Twenty 
(43%) of the 46 tools were related to previously published tools (cf. Fig. A-2). 
 
 
Figure A-2: Relation between different assessment tools. Tools in boxes represent criteria, most frequently 
used as basis for the development of other tools. (Austrian: Austrian Criteria [82]; Beers: Beers Criteria, 
different versions [37, 71, 72]; Beers Liste [83]; German Criteria: Unangemessene Arzneistoffe für geriatrische 
Patienten [84]; IPET: Improving Prescribing in the Elderly Tool [85]; KPC: Kaiser Permanente Colorado Criteria 
[86]; Laroche: Laroche Criteria [87]; Lechevallier: Lechevallier Criteria [88]; Lindblad: Lindblad’s List of Clinically 
Important Drug-Disease Interactions [89]; Maio: Maio Criteria [90]; McLeod: McLeod Criteria [38]; NCQA: 
NCQA Criteria – High Risk Medications (DAE-A) and potentially harmful Drug-Disease Interactions (DDE) in the 
Elderly [91]; New Mexico: New Mexico Criteria [92]; NORGEP: Norwegian General Practice Criteria [93]; 
PRISCUS: The PRISCUS List [94]; Rancourt: Rancourt Criteria [95]; Sloane: Sloane List of Inappropriate 
Prescribed Medicines [96]; Terrell: Terrell Computerized Decision Support System to reduce potentially 
inappropriate prescribing [97]; Zhan: Zhan Criteria [39]) 
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Characteristics (cf. Table A-1, -2 and -3) 
Twenty-eight (61%) of 46 tools were explicit, 8 (17%) were implicit and 10 (22%) used a mixed 
approach. Looking at the patient groups the tools focused on, thirty-six (78 %) tools named 
older people as target patients and 10 (22%) tools did not specify the target age group. Four 
(8.5 %) tools were designed to detect inappropriate prescribing in hospitalized patients, 9 
(19.5%) focused on patients in ambulatory care and 6 (13%) were developed for use in long-
term care. Twenty-seven (59%) tools did not specify the healthcare setting. Consensus 
methods were applied in the development of 19 tools (41%; RAND 2, Delphi technique 16, 
Nominal group technique 1), the others were based on either simple expert panels (13, 28%) 
or on a literature search (11, 24%). For three tools (7%) the development method was not 
described [98-100] 
Aspects of inappropriate prescribing 
The aspect of misprescribing was covered to a different extent by each tool. Fourteen (30%) 
tools focused on overprescribing, 6 (13%) on underprescribing, 8 (17%) mentioned 
nonadherence and 5 (11%) the cost-effectiveness. Fourteen (30%) tools offered alternative 
therapies. 
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 Table A-1: Explicit tools to assess inappropriate prescribing 
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ACOVE QIs - Assessing Care of Vulnerable Elders Quality Indicators [101, 
102](USA, 1999) 
A set of QIs to measure the medical care provided to vulnerable, older persons, 
created in 1999 and twice updated in 2001 (ACOVE-2,  
http://www.rand.org/content/dam/rand/www/external/health/projects/acov
e/docs/acove_qi.pdf) and 2006 (ACOVE-3) [103]. All ACOVE QIs are presented 
in the following format: IF-THEN-(BECAUSE). Not all QIs measure aspects of 
inappropriate prescribing but some consider inappropriate prescribing.   
ACOVE-1 (1999) covers 22 clinical conditions and 236 quality indicators. 
ACOVE-3 (2006) covers 26 clinical conditions and includes 392 quality indicators 
 
. 
ns El ●    ○    ○   ○ 
Dp 
Austrian Criteria [82] (Austria, 2012) 
A list of 73 drugs to avoid in older patients because of an unfavourable 
benefit/risk profile and/or unproven effectiveness. A justification for the 
inappropriateness of a specific drug or drug class is given and for some of the 
drugs safer alternatives are proposed. 
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Beers Criteria [71] (USA, 1991) 
The Beers Criteria, originally developed for nursing home residents, consists of 
19 medications or medications classes to avoid generally in the elderly and 11 
criteria describing doses, frequencies, or durations that should not be 
exceeded. 
Update 1997 [72]: 28 medications or medication classes to avoid generally in 
the elderly and 15 diseases and conditions and medications to be avoided in 
these conditions 
Update 2003 [37]: 48 medications or medication classes to avoid generally in 
the elderly and 20  diseases and conditions and medications to be avoided in 
these conditions  
Update 2012 [73]: 34 medications or medication classes to avoid in the elderly 
and 14 diseases and conditions and medications to be avoided in these 
conditions, and 5 medications to be used with caution in older adults. 
ns El ● ○ ○  ○       ○ 
Dp 
Beers-Liste [83] (Germany, 2007) 
German adaption of Beers Criteria 2003.  Structure and content are similar to 
the original Beers Criteria, but have been adapted for the German Market. 
ns El ● ○ ○  ●       ○ 
Dp 
Laroche Criteria [87] (France, 2007) 
Designed for use in the French healthcare system, including 34 medications to 
be avoided in elderly. Each drug has a declaration for its inappropriateness and 
safer therapeutic alternatives were recommended for most of the criteria. 
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Lindblad’s List of Clinically Important Drug-Disease Interactions [89] (USA, 
2006) 
A consensus list of 28 clinically important drug-disease interactions ordered by 
disease. 
 
A El ●    ●        
Dp 
Malones List of Drug-Drug Interactions [104] (USA, 2004) 
A list of 25 potential harmful drug-drug interactions with clinical importance, 
designed for use in community pharmacies, implemented in a computerized 
alert system. 
 
A ns ●     ●       
Dp 
McLeod Criteria [38] (Canada, 1997) 
Includes 38 inappropriate prescribing practices to avoid in elderly, focused on 
four main topics: 1) drugs to treat cardiovascular diseases, 2) non-steroidal anti-
inflammatory drugs and other analgesics, 3) psychotropic drugs, and 4) 
miscellaneous drugs. For each practice, the risk to the patient is specified and 
an alternative therapy is suggested. 
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NCQA Criteria  - High Risk Medications (DAE-A) and potentially harmful Drug-
Disease Interactions (DDE) in the Elderly [91] (USA,2008) 
The DAE-A and the DDE lists are part of the Healthcare Effectiveness Data 
Information Set (HEDIS), a tool to measure performance on important 
dimensions of care and a service developed by the National Committee for 
Quality Assurance (NCQA). The DAE-A list includes 17 medication classes, which 
should be avoided in the elderly, the DDE list shows medication categories 
affecting the condition of the elderly in a negative way. As a part of HEDIS, the 
DAE-A and DDE lists are available as interactive, web-based reporting software 
and receive regular updates. 
ns El ●    ○        
Dp 
NORGEP - Norwegian General Practice Criteria [93] (Norway, 2009) 
A list of 21 drugs and drug dosages, as well as 15 drug combinations to be 
avoided in the elderly in general practice. Each criterion is specified by a 
comment. 
 
A El ● ○    ●       
Dp 
Rancourt Criteria [95] (Canada, 2004) 
Consists of a list of 111 potentially inappropriate prescriptions categorized as 1) 
Potentially inappropriate medication, 2) Potentially inappropriate dosage 3) 
Potentially inappropriate duration and 4) Potentially inappropriate drug-drug 
interaction.  
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START - Screening Tool to Alert doctors to the Right Treatment [105] (Ireland, 
2007) 
A list of 22 prescribing indicators to identify prescribing omissions in older 
adults. The prescribing indicators are arranged according to the physiological 
system and present information about disease status for which a drug should 
be prescribed. Combining this tool with STOPP (see directly below) is possible. 
ns El ●  ○          
Dp 
STOPP - Screening Tool of Older Person’s Prescriptions [106, 107] (Ireland, 
2008) 
65 criteria focusing on prevalent problems associated with commonly 
prescribed medication, arranged according to physiological systems. Each 
criterion is accompanied by a short explanation concerning the 
inappropriateness of its use. 
 
ns El ● ○ ○ ● ○ ○       
Dp 
The PRISCUS List [94] (Germany, 2010)  
Consists of 83 potentially inappropriate medications in a total of 18 medication 
classes and is designed for use in the German healthcare system. For each 
inappropriate medication, the criteria include main concerns, possible 
therapeutic alternatives and precautions to be taken when these medications 
are used. The freely available online version[108] additionally focuses on drug-
disease interactions. 
 
ns El ● ○   ●       ● 
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Winit-Watjana Criteria [109] (Thailand, 2008) 
The list consists of 77 high-risk drugs divided into drugs to be avoided; drugs 
rarely appropriate; and drugs with some indications for older patients. A 
practice statement for each drug gives additional information about the 
inappropriateness.  
ns El ●    ○ ○       
Dp 
Zhan Criteria [39] (USA, 2001) 
Includes 33 potentially inappropriate medications divided into the categories: 
1) drugs to avoid 2) drugs, appropriate in rare circumstances and 3) drugs with 
some indications but often misused. 
A El ●            
NG
T 
Maio Criteria [90] (Italy, 2010) 
The Italian adaption of Beers Criteria 2003.  The criteria contain 23 potentially 
inappropriate drugs and divide them into three categories: 1) Drugs to always 
be avoided, 2) Drugs rarely appropriate, and 3) Drugs with some indications but 
often misused.  
A El ● ○ ○          
Ex 
American Medical Directors Association -  Top 10 Particularly Dangerous Drug 
Interactions [110] (USA, cited 2011) 
An online list of America’s top 10 dangerous drug interactions for patients in 
long-term care. For each interaction, information about impact, mechanism of 
interactions, alternatives to patient management, monitoring, precautions and 
references were provided. The list is based on considerations of drug-drug 
interactions with clinical significance and a potential to cause harm, the 
frequency with which these interactions occur and the frequency with which 
these drugs are prescribed in nursing homes.  
L ns ●     ●      ● 
●=Aspect totally covered by the criteria. ○=Aspect partially covered by the criteria. Abbreviations: see previous page 
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KPC- Kaiser Permanente Colorado  Criteria [86] (USA, 2007) 
The criteria consist of 11 potentially inappropriate medications for use in elderly 
and suggestions for alternative therapies. The criteria are incorporated in an 
electronic pharmacy information management system. Alerts are generated if 
a drug, included in the Kaiser Permanente Colorado Criteria, should be 
dispensed. For each medication, a specific intervention guideline and patient 
counselling script is defined. 
 
A El ●           ● 
Ex 
Lechevallier Criteria [88] (France, 2005) 
The French adaption of Beers Criteria 1997 includes 24 inappropriate 
prescriptions. Drugs mentioned in Beers criteria but not available in France 
were excluded, drugs available in France belonging to medication classes 
considered inappropriate in Beers Criteria were included.  
 
A El ●   ○         
Ex 
New Mexico Criteria [92] (USA, 2012) 
The New Mexico Prescription Improvement Coalition (NMPIC) created a list of 
72 drugs, based on the Beers criteria [37] and the Zahn criteria, to be used with 
caution in the elderly. The list uses a color-coded scheme to identify different 
severity levels and lists concerns and alternative suggestions for each drug. 
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Lit=based on literature research; El=Elderly; L= Patients in long-term care; H=Hospitalized patients; A=Ambulatory patients; ns = not specified 
 PROJECT A: Inappropriate prescribing  
PhD Thesis Carole Kaufmann 50 
 Table A-1: Explicit tools to assess inappropriate prescribing 
D
ev
el
o
p
m
en
t 
m
et
h
o
d
 
 
H
ea
lt
h
ca
re
 s
et
ti
n
g 
P
at
ie
n
t 
gr
o
u
p
 
Aspects of inappropriateness 
Misprescribing 
O
ve
rp
re
sc
ri
b
in
g 
U
n
d
er
p
re
sc
ri
b
in
g 
C
o
st
 e
ff
ec
ti
ve
n
e
ss
 
N
o
n
-A
d
h
er
en
ce
 
A
lt
er
n
at
iv
e 
th
er
ap
ie
s 
D
ru
g 
ch
o
ic
e
 
D
o
sa
ge
 
D
u
ra
ti
o
n
 o
f 
th
er
ap
y 
D
u
p
lic
at
io
n
 
D
ru
g-
D
is
ea
se
 In
te
ra
ct
io
n
s 
D
ru
g-
D
ru
g 
In
te
ra
ct
io
n
s 
D
ru
g-
Fo
o
d
 In
te
ra
ct
io
n
s 
Ex 
Terrell Computerized Decision Support System to reduce potentially 
inappropriate prescribing [97] (USA, 2009) 
This system was developed for the emergency department and serves as an 
alert system when using one of nine high-use potentially inappropriate 
medications. Safer substitute therapies are proposed. 
H El ●           ● 
Lit 
CMS - List of unnecessary Medications Used in Residents of Long-Term Care 
Facilities [111] (USA, 2006)  
The Centre of Medicare and Medicaid Services (CMS) list of medications which 
have the potential to cause clinically significant adverse consequences, that 
may have limited indications, require specific monitoring, and which warrant 
careful considerations of relative risk and benefit for use in older adults. All 
medications are grouped into a total of 24 medication 
classes/pathophysiological domains. Important information about dosage, 
adverse consequences, indications, interactions, monitoring and duration of 
therapy are added. In an additional table drugs with anticholinergic properties 
that should be avoided in elderly are listed. Beside the medication list, users will 
find a lot of additional tips how to improve medications management. 
L El ● ○ ○  ○ ○       
Lit 
IPET - Improving Prescribing in the Elderly Tool [85] (Canada, 2000)   
The IPET resulted as a shortened version of the McLeod Criteria and consists of 
14 criteria representing potentially inappropriate prescription. Commonly 
encountered drug-disease interactions and medication classes are discussed, 
mostly focusing on cardiovascular and psychotropic drugs.  
ns El ●  ○  ○        
●=Aspect totally covered by the criteria. ○=Aspect partially covered . Abbrev. Ex=Expert panel; Lit=based on literature research; El=Elderly; L= Patients in long-term care; H=Hospitalized 
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Matsumura Alert System for Inappropriate Prescriptions [112] (Japan, 2009) 
A clinical decision support system combined with a computerised physician 
order entry system to aid physicians in prescribing medication appropriately. 
The system focuses on renal disease, liver disease and diabetes mellitus and 
generates alerts in case of inappropriate dosage or contraindication. The alert 
system is patient-specific, changes in therapy parameters and clinical laboratory 
data were automatically updated. 
 
ns ns ● ○   ●        
Lit 
Sloane List of Inappropriate Prescribed Medicines [96] (USA, 2002) 
The Sloane List was developed for identifying inappropriately prescribed 
medications in older patients in residential care/assisted living facilities. The 
Beers Criteria served as its basis. Inappropriate medication is presented 
together with the usual indication, a rationale for being classified as 
“inappropriate”, and possible appropriate alternatives. 
 
L El ●           ● 
Lit 
Unangemessene Arzneistoffe für geriatrische Patienten [84] (DE, 2010) 
German adaption of Laroche Criteria. Structure and content are similar to the 
original Laroche Criteria, but have been adapted to the German market, and 
new recommendations were added. 
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FORTA- Fit for the aged criteria [99, 113] (Germany, 2009) 
A positive list that grades medications into four groups (A-D), concerning their 
evidence for use in the elderly. Category A: indispensable, with obvious benefit, 
B: proven efficacy but limited effects, C: questionable efficacy or safety, should 
be used carefully; D: no evidence, should be avoided in the elderly. Until now, 
the FORTA criteria are not yet fully tested in a clinical setting and an overview 
of recommended drugs is not yet available. 
 
ns El ●            
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Cantrill Indicators of Appropriateness of long term prescribing [114] (UK, 1998) 
Nine indicators of prescribing appropriateness for assessing the entire drug regimen of 
patients on long term medication in general practice.  
 
L ns ● ● ●   ●  ●  ●   
Ex 
Lipton’s Tool to assess the Appropriateness of Physicians’ Geriatric Drug Prescribing 
[115] (USA, 1992)  
Evaluation of each drug in the patient’s regimen in seven categories of potential drug-
therapy problems: 1) Drug allergy, 2) Drug dosage, 3) Drug schedule, 4) Appropriateness 
of drug therapy, 5) Drug-drug interactions, 6) Therapeutic duplication and 7) Prescribing 
omission. For all categories, a score is given: 0=no problem, 1=clinically significant but 
not life-threatening, 2=potentially life threatening or potentially leading to serious 
injury or hospitalisation; 9=not enough clinical information to make an assessment.  
 
ns El ● ●  ●  ●  ●
 
●    
Ex 
MAI - Medication Appropriateness Index [74] (USA, 1992) 
Ten questions used to assess medication appropriateness, which are answered using a 
three-point Likert scale. For each criterion, a rating of 1 represents appropriate 
medication use; a rating of 2 represents marginally appropriate medication use; and a 
rating of 3 represents inappropriate use. 
 
 
 
ns ns ● ● ● ● ● ●  ●  ●   
●=Aspect totally covered by the criteria. ○=Aspect partially covered by the criteria. Abbreviations: RD=RAND method; Dp = Delphi method; NGT = Nominal Group Technique; Ex=Expert panel; 
Lit=based on literature research; El=Elderly; L= Patients in long-term care; H=Hospitalized patients; A=Ambulatory patients; ns = not specified 
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Ex 
PMDRP - Pharmacist’s Management of Drug-Related Problems [116] (Canada, 1997) 
Developed by pharmacists to facilitate learning and the better provision of 
pharmaceutical care. It requires the pharmacists to collect patients’ clinical and medical 
data and serves as a comprehensive documentation system guiding the pharmacists 
through the whole pharmaceutical care process. 
 
ns ns ● ●   ● ● ● ● ●  ●  
Lit 
Barenholtz Levy self-administered Medication-Risk Questionnaire [117] (USA, 2003) 
Ten-item, self-administered questionnaire for use by elderly patients to identify who is 
at increased risk of potentially experiencing a medication-related problem. 
 
ns El ●       ●   ●  
Lit 
Hamdy Criteria for Medication Profile Review in Extended Care [118] (USA, 1995) 
The criteria were developed with the aim of reducing polypharmacy in patients in long-
term care. Five open questions assess the appropriateness of patients’ medication 
focusing on patients taking 10 or more medications. 
 
L ns ● ● ● ● ● ●  ●
 
    
Lit 
Owens Steps to achieve optimal Pharmacotherapy [119] (USA, 1994)  
Consists of five questions: 1) Diagnosis: Is pharmacological intervention necessary? 2) 
Drug appropriateness? 3) Dose appropriateness? Pharmacokinetic and 
pharmacodynamic parameters; 4) Reassess: Is medication still needed? 5) Drug-induced 
disease. 
 
ns El ● ● ●  ●   ●     
●=Aspect totally covered by the criteria. ○=Aspect partially covered by the criteria. Abbreviations: RD=RAND method; Dp = Delphi method; NGT = Nominal Group Technique; Ex=Expert panel; 
Lit=based on literature research; El=Elderly; L= Patients in long-term care; H=Hospitalized patients; A=Ambulatory patients; ns = not specified 
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ns 
Robertson’s Flow Charts to prevent, identify and resolve Drug Therapy Problems [98] 
(USA, 1996)  
Robertson’s Flow Charts were developed to help pharmacy students to focus on drug 
therapy issues during clinical clerkship rotations. Ten flow charts encourage a uniform 
approach to preventing, identifying, and correcting drug therapy problems. 
 
H ns ● ●   ○ ● ● ●  ○ ●  
 
 
 
 
 
 
●=Aspect totally covered by the criteria. ○=Aspect partially covered by the criteria. Abbreviations: RD=RAND method; Dp = Delphi method; NGT = Nominal Group Technique; Ex=Expert panel; 
Lit=based on literature research; El=Elderly; L= Patients in long-term care; H=Hospitalized patients; A=Ambulatory patients; ns = not specified 
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RD 
Australian Prescribing Indicators [120, 121] (Australia, 2008) 
A list of 41 indicators is presented based on the medications most frequently prescribed 
to Australians and the most frequent medical conditions in the elderly. An additional 
list provides criteria usage information containing necessary medical information for 
each criterion. 
ns El ● ○ ○  ○ ●  ○ ○    
Ex 
Brown Model for Improving Medication Use in Home Healthcare Patients [122] (USA, 
1998)  
A list of 15 potential medication problems occurring in patients receiving home 
healthcare. A structured procedure is described, where home health nurses, in 
consultation with a drug utilisation review coordinator (e.g. clinical pharmacist), present 
problems and potential solutions to the patient’s physician. 
A El ● ●  ● ○       ○ 
Ex 
Indicators for Quality Use of Medicines [123] (Australia, 2007) 
The New South Wales Advisory Group Quality Indicators were developed for the 
monitoring of aspects of care in Australian hospitals. Not all of the 30 mentioned 
indicators consider aspects of prescribing. Each indicator is clearly described and usage 
information is provided.   
H ns ○ ○           
Ex 
Oborne’s Prescribing Indicators [124] (UK, 1997) 
A list of 14 prescribing indicators based on the drug charts of 1686 patients. The 
indicators were presented in the form of algorithms guiding the user through the 
process of detecting inappropriate prescribing. A version of Prescribing Indicators 
thought for use in nursing homes is available [125].  
H El ● ○  ○ ○   ○ ○    
●=Aspect totally covered by the criteria. ○=Aspect partially covered by the criteria. Abbreviations: see previous page 
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TIMER - Tool to Improve Medications in the Elderly via Review [126] (USA, 2009) 
Developed to help pharmacists and pharmacy students identify drug-related problems 
during patient medication reviews. TIMER addresses four main categories: 1) Cost-
effectiveness, 2) Adherence, 3) Medication safety, with methods to assess ADEs and 
drug-drug interactions 4) Attaining therapeutic goals 
 
ns El ●   ● ○ ●    ● ●  
Ex 
The Geriatric Medication Algorithm [127] (USA, 1994) 
Designed to educate physicians in reducing inappropriate prescribing, divided into four 
steps: 1) Obtaining a complete medication list from patient and orthostatic blood 
pressure; 2) Evaluating each drug regarding indication, high risk medications and 
dosage; 3) Evaluating the entire drug regimen regarding drug-drug interactions and 
simplification of drug regimen; 4) Evaluating adherence. Some explicit lists of high risk 
drugs and drugs requiring dosage reduction in the elderly are also provided. 
 
ns El ● ●   ● ●  ●   ●  
Lit 
Kaiser Permanente Model [128] (USA, 1995) 
Consists of a pathway for determining high risk patients, then guides the pharmacist 
with a list through Rx-validation and dispensing, and offers drug grids in order to 
improve appropriate interventions.  
 
A ns ● ●  ● ● ●     ●  
●=Aspect totally covered by the criteria. ○=Aspect partially covered by the criteria. Abbreviations: RD=RAND method; Dp = Delphi method; NGT = Nominal Group Technique; Ex=Expert panel; 
Lit=based on literature research; El=Elderly; L= Patients in long-term care; H=Hospitalized patients; A=Ambulatory patients; ns = not specified 
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Medication Management Outcomes Monitor [129] (USA, 2006) 
The criteria focus on reducing inappropriate prescribing (including medication from 
Beers Criteria 1991), decreasing polypharmacy, avoiding adverse events and 
maintaining the functional status of older adults. Those four major outcomes serve as 
an outline and are divided into several specific subgroups, each containing 
bibliographical references or guidelines on how to assess or intervene. These guidelines 
are to be used by registered nurses, nurse practitioners, and pharmacists. 
ns El ● ●  ●    ●  ● ●  
Lit 
POM - Prescribing Optimisation Method for Improving Prescribing in Elderly Patients 
[130] (Netherlands, 2009) 
POM assists physicians to optimise polypharmacy prescribing in the elderly population. 
This method is based on six open questions, whereby each question in presented with 
an overview of the most frequent and clinically relevant problems, together with 
explicit suggestions to improve prescribing. 
ns El ● ●   ● ● ● ● ●  ● ○ 
ns 
ARMOR- A Tool to Evaluate Polypharmacy in Elderly Persons [131] (USA, 2009) 
ARMOR is a stepwise approach for the assessment of a geriatric patient who is: (1) 
receiving nine or more medications; (2) seen for initial assessment; (3) seen for falls 
and/or changes in behaviour; and/or (4) admitted for rehabilitation. The tool consists 
of five steps: Assess (medication), Review (e.g. interactions), Minimise (nonessential 
drugs), Optimise (e.g. Duplication, Dose adjustment) and Reassess (e.g. blood pressure). 
ns El ● ●  ● ● ●  ●     
 
 
●=Aspect totally covered by the criteria. ○=Aspect partially covered by the criteria. Abbreviations: RD=RAND method; Dp = Delphi method; NGT = Nominal Group Technique; Ex=Expert panel; 
Lit=based on literature research; El=Elderly; L= Patients in long-term care; H=Hospitalized patients; A=Ambulatory patients; ns = not specified 
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Table A-4: Correlation of inappropriate prescribing with adverse patient outcomes 
 
 
 
 
 
Tool Outcomes References 
Beers Criteria  - higher probability of hospitalization with 2 or more potentially inappropriate medications (PIM) 
- significantly increased risk for ADRs in elderly with at least one PIM 
- increased risk of hospitalisation and death with PIM 
- increased risk of falling when using PIM 
Albert 2010 [132],  
Ruggiero 2010 [133],  
Passarelli 2005 [70],  
Dedhiya 2010 [134],  
Gallagher 2008 [107] 
Kaiser Permanente Model - lower likelihood of hospitalisation in high-risk patients when using the Kaiser Permanent Model of 
consultation 
McCombs 1998 [135] 
Lipton Criteria -association between the prescribing scores and the number of reported adverse effects Lipton 1993 [136] 
STOPP Criteria - increased risk for ADEs and hospital admission in patients with PIM according to STOPP Hamilton 2011 [137],  
Gallagher 2008 [107] 
NCQA Criteria - Increased risk of hospitalisation with medication on the NCQA list Albert 2010 [132] 
Abbreviation: NCQA: National Committee for Quality Assurance 
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Discussion 
The rapidly growing number of publications about inappropriate prescribing demonstrates the 
increased interest in this topic over the last decade. Many attempts have been made to 
improve drug prescribing. Tools to achieve this aim are numerous, as we show in this 
overview, each with a different structure and degree of comprehensiveness and complexity. 
Many of them might serve as a useful aid to improve prescribing, but each tool has its 
limitations, strengths and weaknesses. In general, an ideal tool to assess the appropriateness 
of drug prescriptions should: 
 cover all aspects of appropriateness (efficacy, safety, cost-effectiveness and patients’ 
preferences) 
 be developed using evidence-based methods 
 show significant correlation between the degree of inappropriateness and clinical 
outcomes 
 be applicable not only in research conditions but also in daily healthcare practice 
None of the tools we describe in this systematic overview covers all aspects of inappropriate 
prescribing. In particular, underprescribing is only mentioned in 6 tools, although 
underprescribing represents an important aspect of inappropriate prescribing and is prevalent 
particularly in the elderly [138]. Many tools strongly emphasize the choice of a drug that leads 
to a better compliance with treatment guidelines. But respecting all relevant treatment 
guidelines without individualisation is in the best case rational prescribing but not necessarily 
appropriate prescribing [139]. Individualisation is therefore a prerequisite for appropriate 
prescribing and, thus, the drug–patient interaction is implicitly included in any aspect of 
appropriate prescribing. 
The development methods of the tools we mapped varied a lot and ranged from those which 
included no information about any aspects of development, to those which used an intensive 
literature search combined with multiple consensus techniques. 
The results obtained from the use of any of the tools represent process measures. Improving 
the patient’s prescription according to such a tool does not necessarily improve outcomes 
(e.g. mortality, morbidity, adverse drug events, quality of life, etc.). Correlations between 
process measures and clinical outcomes should be demonstrated in well-designed clinical 
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trials. For the majority (39/46) of the tools we could not find such clinical validation in the 
literature. 
In a systematic review, Spinewine et al. [32] analysed the correlation between the use of 
inappropriate medications according to the Beers Criteria [37, 71, 72], the McLeod’s Criteria 
[38], and the Medication Appropriateness Index [74] and patient outcomes. Many studies 
examined the Beers Criteria and showed a significant correlation of potentially inappropriate 
medication (PIM) and negative clinical outcomes (e.g., mortality, adverse drug reactions, 
hospital admission). Additional studies not included in Spinewine’s review showed evidence 
that minimizing inappropriate prescriptions may reduce negative patient outcomes (cf. Table 
A-4). 
Assessment tools are not intended as a substitute for the prescriber’s careful clinical decision 
making, even if they have been perfectly validated. Instead, when implemented in daily 
practice, they alert healthcare professionals to the likelihood of inappropriate prescribing [79]. 
Such implementation, however, requires that tools should not only be well designed and 
comprehensive, but also still practical in daily use. Integration of assessment tools in electronic 
decision support systems could be a promising approach [97, 104, 112, 140]. One tool, the 
Barenholtz-Levy Medication Risk Questionnaire [117] is designed for self-assessment by the 
patient which represents a very different strategy. 
A short description of each tool including the number of items, where assessable (cf. Table A-
1, 2 and 3), provides some information about the construction and complexity. The number 
of items per tool varies a lot and ranges from less than ten to more than a hundred items. 
However a direct relation between the number of items and the complexity of a tool is not 
clearly given. As an example: the implicit Medication Appropriateness Index (MAI) [74] 
consists of only 10 questions to patient’s medication. But the application of the MAI requires 
clinical knowledge and is time intensive. On the other hand the explicit Beers Criteria [73], 
with a high number of items, but arranged in a comprehensive way is easy to handle for a 
person who is used to it. 
 
 
 PROJECT A: Inappropriate prescribing  
PhD Thesis Carole Kaufmann 62 
Limitations 
The literature search was restricted to articles published in English and German; criteria 
published in other languages were reasonably not included because analysing and mapping 
the tools required a complete understanding of the text. Literature search, abstract and full 
text screening were done by only one of the authors (RT). Uncertainties were discussed by all 
authors. The mapping was developed by one author (RT) and reviewed by a second (CK). 
Uncertainties about eligibility of a study or classification of the tool were discussed by at least 
three authors.  
Conclusions 
Through a systematic literature search, we identified 46 different tools that assessed 
inappropriate prescribing. They showed a large variety of methodological aspects and 
validation variability. Not surprisingly with such a variety of tools in such a complex field, this 
overview could not identify a single ideal tool but may help readers to choose one, either for 
research purposes or for use in daily practice, according to the situation in which it is intended 
to be applied. By outlining the characteristics in a highly structured manner, this overview may 
reveal strengths and weaknesses, and thus, may stimulate further research in this area. 
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Introduction 
Risk factors for DRPs 
A preliminary definition of characteristics and conditions is required to enable the identification 
of a patient as “being at risk”. 
Clinical pharmacy services for inpatients has been shown to reduce MEs, as well as ADEs and 
ADRs. However, limited resources make it impossible for clinical pharmacists to 
comprehensively monitor every patient’s therapy. Identifying patients at risk for the 
development of DRPs may be an efficient approach to target clinical pharmacy resources to 
those who would benefit the most.  
In pharmaceutical research, studies on the evaluation of risk factors (RFs) for DRPs are 
numerous and are heterogeneous with respect to study design and outcomes. Accordingly, a 
comparison of study results is difficult.  
The most prevalent RF is polypharmacy [16, 141-147], showing the strongest association with 
adverse outcomes. However the definition of polypharmacy varies between the intake of 
“more than 4” to “8 drugs and more”. Besides polypharmacy, polymorbidity [141, 145], renal 
impairment [16, 141, 145, 146] and dementia/impaired cognition [141, 147] are prevalent RFs 
in many studies. Focusing on drugs, most publications highlight oral anticoagulants [16, 141, 
143, 146, 148], diuretics [16, 146, 148], non-steroidal anti-rheumatics [141, 148] and 
antidiabetics [141, 146] as medications with the highest risk of causing harm. A majority of 
studies focused on a quantitative approach to gather these RFs. Variables were mostly 
identified by either a retrospective review of literature, medical records and statistical analysis 
of databases, or a prospective assessment of patient data by the researcher or healthcare 
professionals. Few studies followed a qualitative approach. Howald et al [148] investigated 
the causes of preventable drug-related hospitalisations in the UK. Clinical ward pharmacists 
screened patients admitted to the hospital. Patients with drug-related admissions were 
included. Following patients’ discharge, Howald undertook semi-structured interviews with 
patients (in their home), their GPs, community pharmacists and, if possible, with other 
healthcare professionals involved in the care of this patient. All healthcare professionals were 
independently interviewed at their place of work and answered questions on the patients’ 
medication management and their involvement in their care. The study revealed 
 PROJECT B: Assessment of patients at risk for drug-related problems  
PhD Thesis Carole Kaufmann 65 
communication failures and knowledge gaps, underpinned by a variety of contributing factors, 
including time and workload pressures and problems with computer system design as major 
causes for drug-related hospitalisations. Howald et al. explained the reason for using a 
qualitative approach was the possibility to gathering a more complete picture of the cascade 
of events leading to drug-related hospitalization by conducting interviews. Problems like 
missing data, unverifiable data or fragmented records, which may occur in retrospective 
analyses of data, were therefore overcome. However, the number of cases remained 
relatively small - a well-known limitation of many qualitative studies. 
Data from the literature provided a good basis for the assessment of RFs for DRPs. However, 
we questioned whether these data fully reflect the real-life situation of practicing healthcare 
providers, especially when the information comes from another country with a very different 
healthcare system. In addition, many studies had a narrow focus on specific points in the 
whole care process of a patient For example, the focus may be restricted to hospital admission 
or discharge, or to specific patient groups, such as geriatric patients. 
With this background, we aimed to start our own research and assess RFs for the development 
of DRPs with regard to the entire medication process of a patient in the Swiss healthcare 
system. We followed a triangulation method with a mixed method approach. Triangulation is 
defined as “the use of multiple methods or perspectives for the collection and interpretation 
of data on a certain topic, in order to obtain an accurate representation of reality” [149]. To 
reflect the real-life situation as much as possible we intended to conduct a Nominal Group 
Technique (NGT) besides the literature search, where a panel of healthcare providers could 
share their professional experience and knowledge. NGT is defined below. We were aware 
that qualitative expert interviews were considered as a research method with a low level of 
evidence. To augment credibility, validity and reliability of our findings, we decided to apply 
consensus methods. 
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Consensus methods 
Consensus methods are usually applied when there is a lack of scientific evidence, or when 
there is contradictory evidence on an issue [150]. Consensus methods are group facilitation 
techniques developed to investigate the level of consensus among a group of experts by 
synthesizing and clarifying expert opinions [76]. Well-known consensus methods are the 
Nominal Group Technique (NGT) and the Delphi technique, both of which were used in this 
thesis (cf. project B1) 
NGTs have their use primarily in the generation and prioritisation of ideas [76]. The name of 
the NGT derives from the fact that the technique is nominally a group which is highly 
structured. Adequate advance preparation is a prerequisite for the successful identification of 
the desired information from the panellists [151]. The NGT requires a group facilitator, either 
one who is an expert on the topic, or a credible non-expert [151]. Unlike the Delphi technique, 
there is usually no previous review of the current scientific literature. The facilitator however 
needs to be well informed on the subject to provide panellists with adequate background 
information so that they gain an insight into the context and aim of the meeting [76]. The NGT 
only requires a small group. More than ten to twelve panellists are not recommended because 
it negatively affects the structured discussion and exchange of views. The process of the NGT 
consists of an introduction on the topic by the facilitator. He formulates the nominal question 
and the panellists generate ideas in writing. All ideas are collected on a chart, eventually 
grouped by similar topics and discussed in the group for clarification and evaluation of each 
idea [152]. Afterwards each panellist, privately and anonymously, rank and prioritize all ideas. 
The facilitator collects all data and provides feedback to the panellists. Ratings are then 
discussed and the facilitator might carry out a rerating in order to finalise the results [76]. A 
NGT leads to more ideas than a conventional, unstructured group discussion. Panellists are 
actively encouraged to express their personal view to produce explicit outcomes [151]. For 
data analysis, audiotaping of the NGT is highly recommended and facilitates the generation of 
a transcript afterwards. When conducting face-to-face meetings, attention should be paid to 
the risk of psychosocial bias, especially if the group-composition includes very dominant 
persons or high profile experts. In such cases, some panellists may feel intimidated, and this 
might affect their statements. On the other hand, face-to face meetings, if well directed by 
the facilitator, show the benefit of social interaction. The direct social contact of panellists 
enables an in depth discussion of context and the opportunity to share ideas and experiences 
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[76]. It is the facilitator’s task to create a comfortable atmosphere and to encourage a 
balanced exchange between all participants.  
Like the NGT, the Delphi method is also a decision making process. In contrast to the NGT the 
Delphi method gathers information through an indirect approach. In principle, panellists do 
not meet each other, which may inhibit group dynamics but may also prevent social biases 
[76]. Contact with the participants occurs by questionnaire. The standard process comprises 
a systematic literature review of current evidence that forms the basis for the development 
of the questionnaire. The Delphi technique is a flexible method. Numerous modifications of 
the basic technique have been made [151]. Prior to any ranking process, selected experts may 
also be asked to generate ideas on the given subject, based on their expertise and knowledge, 
to generate items for the later questionnaire[76]. The rating of ideas, primarily gathered in a 
NGT, is also a common approach that we aimed to follow in this thesis. After having received 
the questionnaire, each participant ranks his agreement with every statement. The rankings 
are then summarised and redistributed in a repeat version of the questionnaire. Participants 
rerank, with the opportunity to change their score in view of the group's response. The 
rerankings are summarised again. If an acceptable degree of consensus is obtained the process 
ends, with final results fed back to participants; if not, the third round is repeated [150]. 
For this thesis, we intended to conduct a NGT and let experts generate RFs for the 
development of DRPs. These findings would then be combined with the findings from a 
literature search. Summarized RFs will be used in a Delphi questionnaire and let the same 
panelists who participated in the NGT rank the RFs concerning their relevance for the 
occurrence of DRPs. 
 
Development of a risk-assessment tool 
Once we identified a set of RFs there was the challenge of putting all these RFs in a usable 
form to identify patients at risk for DRPs in a most efficient way. Several approaches for the 
patient identification were discussed. The implementation of the RFs in an electronic patient 
system provides the advantage of a fast, reliable screening without using many human 
resources. The disadvantage is the exclusion of the patients’ opinion who might provide 
important RFs that are not recorded in the electronic data. In addition, electronic patient data 
systems are only partially implemented in Swiss hospitals. The clinical pharmacist or other 
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healthcare providers could assess the patients at risk personally, either by interviewing the 
patient and/or studying medical data. This approach enables a comprehensive report, 
including patient opinion when needed, but is very time- and resource-intensive. We intended 
to create a self-assessment tool, to be filled out by the patient himself. The expert panel 
supported the idea, pharmacists as well as nurses and physicians emphasized that they do not 
have enough time to screen every patient by themselves. Instead of thinking of patients in a 
passive way and treat them as passive recipient of medical care, it can be beneficial to see the 
hospitalized patient as a valuable source of important information and concede him to play a 
little more active role in his own care [153].  
We encountered different risk assessment instruments in the literature. To gain an overview 
what has already been done in this field of research we aimed to create a comprehensive and 
structured overview on all published assessment tools. A mapping, highlighting their 
properties and development method, should serve as orientation and inspiration for the 
intention to modify an existing instrument or to create a new one (cf. overview B3). The tools 
we found where created either for a specific group of patients (e.g. geriatric patients [117, 
145, 154], patients prescribed medicines for cardiovascular disease [155]), tools for the use in 
a special environment (e.g. in an emergency department [147, 156], primary care [154, 157]) 
or tools which assumed the availability of special resources for their application (e.g. 
electronic patient files [158]. Some of the tools were very comprehensive [155, 159] or they 
lacked of information concerning their development or validation [157]. Most of these tools 
where not developed as self-assessment tools for the patient.  
Because we did not find a tool which has met our criteria (patient self-assessment tool, 
applicable to all patients, not focused on a special setting, availability of electronic data not 
needed, easy-to-use and validated) we decided to develop a screening tool by ourselves.  
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We used the following approach: 
 In project B1 we identified RFs for the occurrence of DRPs 
 With project B2 we aimed to create a self-assessment questionnaire out of the identified 
RFs from project B1 and to validate the questionnaire regarding feasibility, acceptability, 
and the reliability of the patients’ answers. 
 In part B3 we aimed to provide an overview on existing risk assessment tools. Because 
researchers from all over the world developed new screening tools, while we were 
developing our own tool, we continued our literature review on risk screening tools and 
included every newly published tool we found in order to provide a very up-to-date 
synopsis about what is going on in this topic. As far as we know, there exists no similar 
overview on risk assessment tools.   
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ABSTRACT 
Introduction and objectives: Drug-related problems (DRPs) constitute a frequent safety issue 
among hospitalised patients leading to patient harm and increased healthcare costs. Because 
many DRPs are preventable, the specific risk factors that facilitate their occurrence are of 
considerable interest. The objective of our study was to assess risk factors for the occurrence 
of DRPs with the intention to identify patients at risk for DRPs to guide and target preventive 
measures where they are needed most in patients. 
Design: Triangulation process using a mixed method approach. 
Methods: We conducted an expert panel, using the nominal group technique (NGT) and a 
qualitative analysis, to gather risk factors for DRPs. The expert panel consisted of two 
consultant hospital physicians (internal medicine and geriatrics), one emergency physician, 
one independent general practitioner, one clinical pharmacologist, one clinical pharmacist, 
one registered nurse, one home care nurse and two independent community pharmacists. 
The literature was searched for additional risk factors. Gathered factors from the literature 
search and the NGT were assemble and validated in a two-round Delphi questionnaire. 
Results: The NGT resulted in the identification of 33 items with 13 additional risk factors from 
the qualitative analysis of the discussion. The literature search delivered another 39 risk 
factors. The 85 risk factors were refined to produce 42 statements for the Delphi online 
questionnaire. Of these, 27 risk factors were judged to be ‘important’ or ‘rather important’. 
Conclusions: The gathered risk factors may help to characterise and identify patients at risk 
for DRPs and may enable clinical pharmacists to guide and target preventive measures in order 
to limit the occurrence of DRPs. As a further step, these risk factors will serve as the basis for 
a screening tool to identify patients at risk for DRPs. 
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Strengths and limitations of the study 
 This research project followed a comprehensive triangulation method to gather risk 
factors for drug-related problems (DRPs), integrating expert opinion and literature data, 
which represents — to the best of our knowledge, a new approach in this topic. 
 Participating experts represented a wide variety of settings of patient care and steps in 
the medication process. This allowed a broad view on the topic of DRPs. 
 Inviting actively practising healthcare professionals as experts ensures the practical 
relevance of gathered risk factors. 
 The restricted number of participants in the nominal group technique may have limited 
the diversity of risk factors. 
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Introduction 
Drug-related problems (DRPs), defined as ‘an event or circumstance involving drug therapy 
that actually or potentially interferes with desired health outcomes’[4], constitute a frequent 
safety issue among hospitalised patients leading to patient harm and increased healthcare 
costs. The term DRP embraces medication errors (MEs), adverse drug events (ADEs) and 
adverse drug reactions (ADRs). An ME is ‘any preventable event that may cause or lead to 
inappropriate medication use or patient harm while the medication is in the control of the 
healthcare professional, patient or consumer’[5]. An ADE can be defined as ‘an injury—
whether or not causally related to the use of a drug’[6]. ADRs include ‘any response to a drug 
which is noxious and unintended, and which occurs at doses normally used in humans for 
prophylaxis, diagnosis or therapy of diseases, or for the modification of physiological 
functions’[160]. In a systematic review of the years from 1991 to 2001, Krähenbühl-Melcher 
et al [16] found that approximately 8% of hospitalised patients experience an ADE, and 5–10% 
of all drug prescriptions or drug applications are erroneous. In general internal medicine, 
about 15% of hospitalised patients and 12–17% of patients after discharge experience ADEs 
[17, 161]. In a group of 435 patients with discharge prescriptions from six different European 
countries, Paulino et al [18] found a DRP in at least 63% of cases. In a Swiss study, 89 of 264 
(34%) discharge prescriptions contained qualitative deficiencies and 72 (27%) showed DRPs 
[20]. Thus, unplanned medication-related readmissions within a short time after discharge are 
frequent. In a multicenter observational study with a prospective follow-up, 5.6% of 12’793 
unplanned admissions were medication related and of these 46.5% were potentially 
preventable [15]. 
Because DRPs are an important problem and many of them are preventable, the specific risk 
factors that facilitate the occurrence of DRPs are of considerable interest. Previous studies 
have determined numerous risk factors for DRPs. In a literature review, female sex, 
polypharmacy, administration of drugs with a narrow therapeutic range or renal elimination, 
age over 65 years, and the use of oral anticoagulants and diuretics, were identified as relevant 
risk factors for ADEs and ADRs [16]. Leendertse and colleagues considered risk factors, such 
as four or more comorbidities, polypharmacy, dependent living situation, impaired cognition, 
impaired renal function and non-adherence to medication regimen, as independent and 
significant risk factors potentially responsible for preventable hospital admission [15].  
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These publications mostly rely on retrospective data and often focus on specific points in the 
whole care process of a patient, for example, hospital admission or discharge. Thus, data from 
the literature might not fully reflect the current problems of practising healthcare providers, 
especially when the information comes from another country with a completely different 
healthcare system. Few studies used a qualitative approach and attempted to reflect real life 
situations by interviewing patients and healthcare providers. Risk factors reported in such 
studies differed from those found in quantitative studies. Howard et al [162] conducted 
qualitative interviews with patients, general practitioners and community pharmacists, and 
concluded that communication failures and knowledge gaps at multiple stages in the 
medication process are important risk factors for preventable drug-related admissions. A 
combination of a qualitative as well as quantitative approach in gathering risk factors for DRPs 
has not been very prevalent in the current literature. 
The aim of our study was to determine the individual risk factors for DRPs by combining 
current evidence from the literature with the professional experience of healthcare providers 
throughout the entire medication process. A triangulation process with quantitative and 
qualitative research methods in combination with consensus techniques served as a 
comprehensive approach to bridge the gap between research results and professional 
experience. It is hoped that this will lead to a list of risk factors for DRPs that accurately reflects 
the reality of daily practice. Risk factors collected will help to characterise and identify patients 
at risk for DRPs and will enable clinical pharmacists to guide and target preventive measures 
in order to minimise the occurrence of DRPs. 
 
Methods 
Nominal Group technique 
We used the nominal group technique (NGT) as a method for eliciting risk factors [76, 151, 
152]. We set up an expert panel consisting of two consultant hospital physicians (internal 
medicine and geriatrics), one emergency physician, one independent general practitioner, one 
clinical pharmacologist, one clinical pharmacist, one registered nurse, one home care nurse 
and two independent community pharmacists. The selection was based on the desirability of 
including a wide variety of experts from different settings, who are all involved in the patients’ 
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medication management. Every expert had at least 5 years of professional experience, held a 
senior/executive position and was involved in daily patient care.  
We set the duration of the NGT to 2 h. The moderator (CK) started the NGT meeting with a 
short introduction to the topic, with the aim of communicating the goal of the meeting and 
bringing the entire panel’s knowledge about DRPs up to the same level. The participants were 
then asked to write down as many risk factors for DRPs as they could spontaneously think of. 
To avoid double-nominations, synonyms and very closely related terms (e.g., ‘dementia’ and 
‘cognitive impairment’), two clinical pharmacists (MLL and DS) and a community pharmacist 
(KEH) grouped the gathered risk factors while retaining each individual factor in the list. This 
work was done during the NGT. Subsequently, we presented the collected risk factors to the 
participants and invited them to rank each risk factor by its relevance. Each expert allocated 
50 points (1.5 times the number of risk factors (=33)). We determined the amount of points 
by ourselves. Experts should be able to rank every risk factor, instead of choosing a defined 
number of most important factors. However, we limited the amount of points to force a 
consensus finding. Experts could assign as many points to as many of the risk factors as they 
wanted until all points were used. After the first ranking, we collected the ranking sheets and 
summarized the points to create a first ranking list. We discussed the ranking list with the 
expert panel, paying special attention to high and low scoring and discrepancies in the ranking 
among participants. In the second round of the ranking process, panellists had only as many 
points as the number of available risk factors, forcing them to fine-tune their previous ranking 
and to reach a consensus. We collected the rerated lists, created the new ranking, and then 
returned the resulting ranking list to all participants for final comments. Because we worked 
neither with patient data nor with patients themselves, we did not need ethical approval.  
We audiotaped the entire discussion session of the expert panel and transcribed it into written 
text for qualitative analysis. One of the authors (DS) split the transcript into fragments and a 
second author (CPK) checked the splitting. Later the two authors (DS and CPK) together 
rearranged the fragments into groups treating related subjects. The whole grouping was then 
discussed by three authors (CPK, DS and MLL). Disagreements were discussed until the three 
authors reached consensus. We labelled every fragment with a unique index number to assure 
transparency. 
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Literature search 
We conducted a non-systematic literature search to supplement the findings of the expert 
panel. Our goal was to gain an impression of the current state of research in the field of risk 
factors leading to DRPs. We wanted to know which risk factors for DRPs were described in the 
current literature and which were most mentioned. We conducted our search in PubMed and 
EMBASE. Language was restricted to German and English. The following search terms wer 
used in EMBASE: ‘drug related problems’ AND ‘risk’/exp AND factors AND [systematic 
review]/lim AND ([english]/lim OR [german]/ lim) AND [humans]/lim.; ‘Triage’/exp OR 
‘triage’/syn AND (‘risk’/exp OR ‘risk’/syn) AND assessment AND ([child]/lim OR 
[adolescent]/lim OR [adult]/lim OR [aged]/lim) AND [humans]/lim AND [english]/lim AND 
([meta-analysis]/lim OR [systematic review]/lim) AND ([article]/lim OR [review]/lim).; 
‘Adverse drug reaction’/exp AND ‘screening’/exp AND ‘high risk patient’/exp AND 
[humans]/lim AND [english]/lim 
The following search terms were used in PubMed: “Triage/methods”[MAJR] AND “Risk 
Assessment/methods”[MeSH Terms]; “Drug Toxicity”[MAJR] AND “Risk 
Assessment/methods”[MeSH Terms]; ((“Drug Toxicity”[Mesh]) OR “Medication 
Errors”[Mesh]) AND “Triage/methods”[MAJR] AND “Risk Assessment/methods”[MeSH 
Terms]; “Medication Errors”[Mesh] AND “Triage/methods”[MAJR] AND “Risk 
Assessment/methods”[MeSH Terms]; (“Risk Factors”[MeSH Terms]) AND 
“Hospitalization/statistics and numerical data” [MAJR] “Risk Assessment/methods”[MeSH 
Terms] AND “Medication Errors”[Mesh] 
Titles and abstracts were screened for relevance. Abstracts needed to mention the terms ‘risk 
factors’, ‘predictors’ or ‘high risk’ in combination with ‘drug-related problems’ or subterms of 
its definition. 
We checked the reference list of each paper selected for further possible hits. Besides this 
literature search, we reviewed different tools focusing on the assessment of inappropriate 
prescribing, which we identified in a previous systematic review [163]. Inappropriate 
prescribing is a known source of DRPs, ADEs and ADRs. Original publications of these tools 
were screened for risk factors associated with inappropriate prescribing that are connected 
with negative outcomes, for example, DRPs, ADEs, ADRs and rehospitalisation. PubMed and 
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EMBASE were searched for validation studies using the name of the tool and, if necessary, 
‘outcome’ or ‘assessment’ as MeSH terms or by checking publications that cited the original 
paper. 
Delphi process 
We validated the risk factors collected from the literature search and the NGT by using the 
Delphi technique [164]. Before integrating the risk factors in the questionnaire, we condensed 
them by using the following exclusion criteria: 
 The risk factor is mentioned in only one of the relevant publications. 
 The risk factor set in the lowermost quartile of our NGTs ranking list is not mentioned 
anywhere else. 
 The risk factor is categorised as an issue of seamless care (e.g. lack of communication 
between healthcare professionals, patient information and discharge management). 
 The risk factor represents a barely predictable event or circumstance (e.g. unscheduled 
discharge, confusion of drug names by professionals). 
We excluded seamless care issues, because they are not individual risk factors but instead 
reflect system failures; they are, therefore, not assessable for an individual patient. In 
addition, we combined synonyms in one term. Any ambiguous risk factors were discussed by 
experts to decide about their inclusion or exclusion on a case-by-case basis.  
In a two-round online Delphi survey (Flexi Form, In 2.0 ed.), following 2 months after the NGT, 
the NGT participant rated each risk factor on a four-item Likert scale (1=‘unimportant’ 
2=‘rather unimportant’, 3=‘rather important’, 4=‘important’) according to its potential to 
cause DRPs (cf. Annex A1.1). 
The questionnaire for the second rating started 2 weeks after the end of the first rating and 
included the same questions as the first one, but the sequence represented the ranking list of 
the first round. We presented the median score and the interquartile range (IQR) of each 
question to the participants to give them the possibility to consider the group’s rating for their 
own re-rating. Below the Likert scale of each question, the number of participants who rated 
for the respective relevance was shown. After the second rating, the median scores and IQRs 
were calculated and a final ranking list of risk factors collected was established.  
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Results 
NGT rating and literature search 
The ranking process of the NGT resulted in 33 items (figure B1-1). The qualitative analysis of 
the discussion not only confirmed risk factors identified in the rating process but also revealed 
13 additional risk factors. Main topics were high-risk drugs, communication issues between 
healthcare professionals, patient education and questions of responsibility. The literature 
search resulted in 39 additional factors that were not mentioned in the NGT. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B1-1: Flowchart of eliciting risk factors possibly leading to DRPs (NGT, nominal group technique; DRPs, 
drug-related problems). 
 
 PROJECT B: Assessment of patients at risk for drug-related problems  
PhD Thesis Carole Kaufmann 79 
Delphi questionnaire 
In total, we gathered a preliminary list of 85 risk factors. Of these, we excluded 38 risk factors 
because they fulfilled our exclusion criteria (cf. table B1-1). Twice, we split a risk factor into 
two parts, and we eliminated seven synonyms. Ultimately, we used 42 risk factors in the 
Delphi questionnaire. 
The results of the Delphi technique are shown in tables B1-2 and B1-3. They are arranged by 
median score of the second round. In the second round, 10 risk factors were judged as 
‘important’ (Likert scale: 4) concerning their contribution to the occurrence of DRPs, 17 risk 
factors were judged as ‘rather important’ (Likert scale: 3), 15 risk factors were judged as 
‘rather unimportant’ (Likert scale: 2) and no risk factor was considered as ‘unimportant’ (Likert 
scale: 1). The sum of the IQRs changed from 30 in the first round to 20 in the second round, 
representing a stronger consensus between the participants. Finally, we created a list of 27 
risk factors rated as important or rather important for the occurrence of DRPs. 
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Table B1-1: Risk factors excluded from the Delphi questionnaire, including information to their origin.  
Abbreviations: L: Literature search, N: NGT ranking list, Q: Qualitative analysis of the NGT 
Excluded risk factors 
Mentioned in only one of the selected 
publications 
heart failure (L); liver disease (not hepatic impairment) (L); problems with “water works”(L); 
antidepressant (L); drugs with positive inotrope effects (L), potassium channel activators (L); 
antibacterial drugs (L); laxatives (L); corticosteroids for inhalation (L), loperamide (L); statins (L); 
cephalosporins (L); compound analgesics (with opioids )(L); low molecular weight heparins (L); 
macrolide antibiotics (L); penicillin (L); aspirin (L); salbutamol (L); antihypertensives (L); bladder 
antimuscarinic drugs (L); cerebral vasodilators (L); nitroglycerine (L); ranitidine (L); 1st generation 
antihistamines (L) 
 
Lowermost quartile of the NGT ranking list and not mentioned 
elsewhere 
money (N); Morbus Parkinson (N); xerostomia (N); oral bisphosphonate (N) 
Seamless care issue or intervention to improve 
seamless care  
OR 
Unpredictable event or circumstance 
unclear prescription/unclear or non-available dosage regimen at discharge (N); multiple treating 
physicians (L,N); missing instruction of relatives(N); medication-taking gap (N); briefing of the patient 
(L;Q);  confusion of drug names (N); new medication / lots of changes/ alternating dosages (N); 
changes in therapy: stop due to hospitalisation/discharge/generic medication (N,Q); unscheduled 
discharge (N) 
Synonyms 
- behaviour at home during an ADR (N); earlier experiences with medication (N,Q)  included as: experience with ADR (Q) 
- impaired mobility (L,N)  included as:  High risk of falls, motion insecurity (L,N,Q) 
- language (Q)  included as: language issues (N) 
- oral corticosteroid (L); systemic corticosteroids (L)  included as: corticosteroids (L) 
- parallel therapy (N) incl. as: self-medication with non-prescribed medicines (N,Q) 
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Table B1-2: Final ranking list of the 27 risk factors contributing to the occurrence of DRPs rated by the expert panel as “important” (Likert scale: 4) or “rather important” 
(Likert scale: 3). 
Risk factor            Delphi 
Median        IQR 
NGT Literature 
Ranking 
list 
Qual. 
anal. 
Dementia, cognitive situation,  
Low IQ, confused patient 
4 4.00 – 4.00 YES  [15], [156], [147], [165], [107] 
Polypharmacy (number of drugs >5) 4 4.00 – 4.00 YES YES [15], [156], [147], [143], [145], [16] 
Antiepileptics 4 4.00 – 4.00  YES [148, 166], [107], [137] 
Anticoagulants 4 4.00 – 4.00  YES [15], [143], [148], [167], [16] 
Combinations of non-steroidal anti-inflammatory  
drugs (NSAID) and oral anticoagulants 
4 4.00 – 4.00  YES [107] 
Insulin 4 4.00 – 4.00 YES  [15], [148, 166] 
Missing information, half-knowledge of the patient, the patient does not understand the 
goal of the therapy 
4 4.00 – 3.25 YES  [162] 
Medication with a narrow therapeutic window 4 4.00 – 3.25 YES YES [16] 
Non-adherence 4 4.00 – 3.00 YES  [15] 
Polymorbidity 3.5 4.00 – 3.00 YES YES [15], [145] 
Digoxin 3 4.00 – 3.00   [166], [107], [115] 
Renal impairment (eGFR <30 ml/min) 3 4.00 – 3.00 YES  [15], [145], [107] 
NSAIDs 3 4.00 – 3.00  YES [15], [143], [148, 166], [16, 137] 
Experience of ADR 3 3.75 – 3.00 YES YES [145] 
Medication which is difficult to handle  3 3.75 – 3.00 YES   
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Risk factor            Delphi 
Median        IQR 
NGT Literature 
Ranking 
list 
Qual. 
anal. 
Language issues (i.e. non-native speakers ) 3 3.00 – 3.00 YES YES  
Diuretics 3 3.00 – 3.00  YES [15], [148, 166], [167], [165], [137], 
[16] 
Tricyclic antidepressants 3 3.00 – 3.00   [143], [107] 
Hepatic impairment 3 3.00 – 3.00 YES  [145], [107] 
Self-medication with non-prescribed medicines 3 3.00 – 3.00 YES YES  
Impaired manual skills (causing handling difficulties) 3 3.00 – 3.00 YES   
Visual impairment 3 3.00 – 3.00 YES YES [156] 
Anticholinergic drugs 3 3.00 – 3.00   [168] 
Benzodiazepines 3 3.00 – 3.00   [143], [107], [168], [137], [169] 
Opiates/Opioids 3 3.00 – 3.00   [15], [148], [167], [107], [137] 
Corticosteroids 3 3.00 – 2.00   [15], [148, 166] 
Oral antidiabetics 3 3.00 – 2.00   [15], [148, 166] 
 
 
 
 
The sequence represents the ratings of the Delphi survey indicating median ratings and IQR, and appearance in the NGT ranking list, the qualitative analysis of the NGT and in the literature. 
Factors with no reference in the literature section were only mentioned by the experts. IQR, interquartile range; ADR, adverse drug reaction; DRP, drug-related problem; eGFR, estimated 
glomerular filtration rate; NGT, nominal group technique; NSAID, non-steroidal anti-inflammatory drugs. 
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Table B1-3 Risk factors contributing to the occurrence of DRPs rated from the expert panel as ‘rather unimportant’ (Likert scale: 2) or ‘unimportant’ (Likert scale: 1) and 
therefore not included in the final list of risk factors 
Risk factor            Delphi 
Median            IQR 
NGT Literature 
Ranking 
list 
Qual. 
anal. 
Age 2.5 3.75 – 2.00  YES [170], [16] 
Extreme body weight (too high or too low) 2 3.00 – 2.00 YES   
Antiplatelet drugs 2 3.00 – 2.00   [15], [148, 166] 
Drugs affecting the renin-angiotensin-aldosterone-system (RAAS) 2 3.00 – 2.00   [15], [148] 
Patient living alone 2 3.00 – 2.00 YES  [147], [165], [171] 
Calcium antagonists 2 3.00 – 2.00   [15], [148], [107] 
Nitrates 2 3.00 – 2.00   [148, 166] 
Patient’s education about his therapy 2 2.75 – 2.00  YES [162] 
Beta-blockers 2 2.00 – 2.00   [15], [148, 166], [107], [137] 
Antacids 2 2.00 – 2.00    
High risk of falls, motion insecurity 2 2.00 – 2.00 YES YES [147], [165], [171], [107], [137], [168], [169] 
Previous hospitalisation in the last 30 days 2 2.00 – 2.00   [156], [147], [170] 
Need for caregiver at home 2 2.00 – 2.00 YES  [15] 
Calcium containing drugs 2 2.00 – 1.00   [115] 
Respiratory drugs 2 3.00 – 1.00   [15], [148], [167] 
The sequence represents the ratings of the Delphi survey indicating median ratings and IQR, and appearance in the NGT ranking list, the qualitative analysis of the NGT and in the literature. Factors 
with no reference in the literature section were only mentioned by the experts. IQR, interquartile range; DRP, drug-related problem; NGT, nominal group technique; RAAS, renin-angiotensin-
aldosterone system. 
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Discussion 
We were able to determine 27 risk factors that appear to contribute substantially to the 
occurrence of DRPs. The triangulation, for which we used the NGT with its rating process, the 
expert panel and a literature search, enhanced the accuracy of our findings and ensured their 
practical relevance. In agreement with previous quantitative studies, we identified expected 
and well-known risk factors in our literature search. The inclusion of an expert panel gave us 
valuable insight into problems healthcare professionals are confronted with and the risk 
factors they judge as important or not. As we expected, risk factors that were prevalent in the 
literature were mentioned by the experts as well, for example, some high-risk drugs (such as 
anticoagulants and insulin), polypharmacy and renal impairment. Apart from that, the expert 
panellists showed us valuable risk factors often seen in their daily practice and less described 
in the literature. Insufficient information transfer between the primary and secondary care 
setting was considered as important handicap in daily practice. Problems are considered to 
have already begun at hospital admission, where patients often arrive without being able to 
give information about their current longterm medication. During the hospital stay, the 
medication of the patient undergoes significant changes. Lack of communication among the 
different healthcare providers leads to confusion. 
Community pharmacists reported about having insufficient access to patients’ medical 
records, which hinders them in advising the patient in a comprehensive way. Panellists from 
every healthcare area emphasised the importance of patient information. They were aware 
that patients’ knowledge about their medication is often incomplete. Self-medication is rarely 
mentioned in the dialogue with the healthcare professionals because the patient does not 
regard their vitamin pills and herbal supplements as real medication. 
An increasing number of patients speaks a foreign language, which complicates 
communication. To improve the education of patients and to guarantee the transfer of 
information about patients’ medication, panellists acknowledged the benefit of appointing an 
individual who would be responsible for the medication management and education of the 
patient. 
The experts stated that the medication manager would ideally be someone who could walk 
across all floors of the hospital, meeting with newly admitted patients, compiling a complete 
 PROJECT B: Assessment of patients at risk for drug-related problems  
PhD Thesis Carole Kaufmann 85 
medication history and checking for DRPs. This medication manager would monitor the 
patient throughout the hospital stay and, at the patient’s discharge, he or she would perform 
the final medication check to identify potential DRPs, and ensure that the patient understands 
the prescribed therapy and knows how to take the medication. After discharge, the 
medication manager would ensure that the correct information is shared with the community 
pharmacy and the general practitioner in order to guarantee seamless care. The medication 
manager would serve as a consultant and not as a replacement for the prescribing physician. 
The panellists considered clinical pharmacists or pharmacologists the most appropriate 
professionals for this task, due to their broad knowledge about medication. 
The risk factor ‘age’ does not belong to the final list of most important risk factors. The experts 
stated clearly that an 80-year-old patient could be in a much healthier condition than one who 
is a 60 years old. When talking about geriatric patients, we are aware of risk factors such as 
polypharmacy, renal impairment, dementia and many more. The expert panel rated these risk 
factors as more important than the ‘age’ factor itself. 
The composition of the expert panel was multidisciplinary by choice, because we aimed to 
bring together all stakeholders in the medication process of a patient. By performing an NGT 
instead of interviews, we gave the panellists the possibility not only to answer our questions, 
but to discuss their different views with other healthcare professionals. The panellists were 
highly motivated and discussed in an engaged and informative way. Despite their different 
professional backgrounds, they agreed on many discussion points. They appreciated the 
interdisciplinary exchange and found that it would be worthwhile to conduct such discussion 
rounds more frequently. 
The ensuing Delphi process enabled the desired consensus-forming. By conducting the Delphi 
process with online questionnaires, where the participants were anonymous, we avoided any 
psychosocial biases. In the first round, the total number of IQRs was 30, whereas it was 20 in 
the second round. This means that the degree of consensus increased among the participants. 
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Study limitations 
There are some general concerns about the validity and generalisability of information created 
by qualitative research methods. The Delphi and NGT approaches are both often criticised for 
showing a lack of research-based evidence concerning diverse feedback methods, and their 
influence on the validity and reproducibility of the decisions reached by the panel members 
[151]. Other influences on the whole group dynamic are psychosocial biases, which were 
described by Pagliari et al [172]. We addressed this by assigning each panellist a place in the 
NGT in order to avoid grouping of friends or panellists from the same profession. We decided 
to use a small expert panel with 10 panellists. Although larger groups would provide a more 
extensive representation, they may be difficult to lead, which may only be resolved by 
introducing more structure and role definition into the process [172]. 
A limitation of our Delphi technique after employing NGT is the restricted number of 
participants. We chose the very same motivated experts for the Delphi and the NGT, because 
they were already familiar with the topic. In conclusion, the gathered risk factors may help to 
characterise and identify patients at risk for DRPs, and may enable clinical pharmacists to 
guide and target preventive measures in order to limit the occurrence of DRPs. In a further 
step, these risk factors will serve as the basis for a screening tool to identify patients at risk for 
DRPs. 
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ABSTRACT 
Background and Objectives: Drug-related problems (DRPs) are a serious concern among 
hospitalized patients, leading to harm and increased health-care costs. Identifying patients 
with a high risk for drug-related problems (DRPs) might optimise the allocation of targeted 
clinical pharmacy activites during the hospital stay and upon discharge. The objective of this 
study was to develop a self-assessment screening tool to identify patients at risk for DRPs and 
validate the tool regarding feasibility, acceptability, and the reliability of the patients’ answers.  
Design and Setting: Prospective validation study in two mid-sized hospitals in Basel-Land, 
Switzerland.  
Methods: Twenty-seven risk factors for the development of DRPs, evaluated in a previous 
study, provided the basis for the Drug-Associated Risk Tool (DART). Consenting patients filled 
in the DART, and we compared their answers with objective patient data from medical records 
and laboratory data. Exclusion criteria were age under 18 years, ambulatory or palliative 
patients, or a health status not allowing meaningful communication. 
Results: One hundred and sixty-four patients (median age: 74 years [age range: 20-95 years], 
49% female) filled in the DART in an average time of 7 minutes. The questions of the DART 
reached an overall specificity of 0.95 (range: 0.82-1), whereas the overall sensitivity was 0.58 
(range: 0.21-1).  
Conclusions: The new DART self-assessment questionnaire showed a satisfying feasibility and 
reliability. False positive results can be excluded with a high probability of success due to 
constantly high specificity values. The sensitivity varied and was higher in statements 
concerning diseases that require regular disease control and daily attention to self-care and 
drug management. Drugs requiring a high amount of self-management showed the highest 
sensitivity. Despite some low sensitivity values, this questionnaire seems to be applicable to 
patients in a hospital setting. Patients may be a valuable, but often neglected source of 
information. Asking patients about their conditions, their medications and related concerns 
and problems can facilitate getting a first, but broad picture of the risk for DRPs and possible 
pharmaceutical needs. To strengthen the reliability of the DART some questions should be 
rephrased and risk factors with a very low prevalence should be validated in a more specific 
population.   
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Impact of findings on practice statements 
 A self-assessment questionnaire as a screening for risk factors that could lead to drug-
related problems is a new approach and seems acceptable and feasible 
 Patients may be a reliable source for information about drug therapy issues and 
related risk. 
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Introduction 
Drug-related problems (DRPs) are a frequent issue among hospitalised patients, leading to 
patient harm and increased healthcare costs [16]. Many unplanned admissions are 
medication-related [141] and a considerable number could be prevented [10]. Complexity and 
often poorly designed processes foster the development of drug-related problems inside and 
outside of the hospital. A study from Switzerland showed that 36% of all discharge 
prescriptions contained technical DRPs like unreadable prescriptions, missing drug form and 
package size, and 19.6% showed clinical DRPs like drug-drug interactions, inappropriate drug 
choice and wrong dosing [20]. Not surprisingly, a remarkable number of patients experience 
adverse drug events (ADEs) after discharge [161]. 
Clinical pharmacy services in hospitals have been shown to increase patient safety by reducing 
medication errors and Adverse Drug Events (ADEs), as well as adverse drug reactions (ADRs). 
They increase medication appropriateness, improve patients’ knowledge about drug therapy 
and adherence, and finally reduce the length of hospital stays [54]. Limited resources and 
capacities force clinical pharmacists to target their clinical activities to those patients who are 
most likely to benefit therefrom, or in other words, to those who are at the highest risk of 
experiencing DRPs, and in consequence, ADEs. An effective screening tool to identify high-risk 
patients might prove a successful approach. How do we characterize a patient at risk? The 
literature provides us with well-known risk factors for the development of DRPs, for example, 
polypharmacy, renal impairment, or the use of non-steroidal anti-inflammatory drugs 
(NSAIDs) [141, 143, 148]. There are some available risk assessment tools which focus on 
various combinations of these risk factors. Most of them are created either for a specific group 
of patients (e.g. those with renal impairment [173], geriatric patients [145, 154], patients 
prescribed medication for cardiovascular disease [155]), tools for the use in a special 
environment (e.g. in an emergency department [174]) or tools which need special resources 
to be applied in hospital (e.g. computerized patient files [175]). These tools often have the 
disadvantage of being time and personnel intensive; some are hardly applicable without 
electronic data or they have not been validated. 
Therefore, we decided to develop a new risk assessment tool from the ground up. The “Drug-
Associated Risk Tool (DART)” should serve as a reliable, easy-to-use screening instrument to 
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detect patients at risk for DRPs. To save personal resources and time, we set out to develop a 
self-assessment questionnaire that can be filled in by the patients themselves.  
 
In a previous study [176], we identified 27 risk factors for the development of DRPs, which 
provided the basis for the self-assessment questionnaire. We searched for relevant risk 
factors, not only in literature, but also by using qualitative research. We conducted an expert 
panel discussion to get a deeper insight into everyday practice, and by doing so, to identify 
additional risk factors that had been neglected in literature.  
The aim of this study was to create a self-assessment questionnaire out of the identified risk 
factors and to validate the questionnaire regarding feasibility, acceptability, and the reliability 
of the patients’ answers by assessing sensitivity and specificity. 
Ethical approval 
The local ethics committee (Ethikkommission beider Basel) approved the study (cf. Annex 
A2.1). All participating patients gave informed consent (cf. Annex A2.2) 
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Method 
Our study was divided in two parts: First the development of the self-assessment 
questionnaire and second its validation. 
 
Development of the questionnaire 
Twenty-seven risk factors for the development of DRPs, collected in a previous study [176], 
provided the basis for the self-assessment questionnaire. With the intention of creating a 
questionnaire for patients, we translated each risk factor into statements that could be 
answerable by medical laypersons (cf. table B2-1).  
We covered the risk factor “non-adherence” with a question that we retrieved from a 
validated questionnaire, the Morisky Medication Adherence Scale MMAS-8 [177], a validated 
self-report 8-item questionnaire, widely used to measure adherence. Risk factors concerning 
patients’ beliefs about medicines in general were covered by using four questions from the 
Beliefs about Medicines Questionnaire BMQ [178], a questionnaire that comprised two five-
item scales assessing patients’ opinions about the necessity of prescribed medication for 
controlling their illness and their concerns about the potential adverse consequences of taking 
it. 
Amateur test 
Prior to the study, we conducted an amateur test and asked ten medical laypersons from the 
personal environment of the authors (no patients) to fill out the DART. We did not provide 
any support during its completion. We asked each individual for his/her judgment concerning 
the comprehensibility of the statements.  
 
Validation of the questionnaire 
Study design and Setting 
For the prospective validation study, we recruited the patients in two mid-sized hospitals with 
each 400 beds in Basel-Land, Switzerland. We recruited on the orthopaedic, geriatric, and 
internal medicine wards.  
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Patient Selection 
Eligibility criteria were age over 18 years, ability to speak German in order to communicate 
with the investigator, and the patient required hospitalization. We excluded ambulatory 
patients and patients with a health status not allowing a meaningful communication (e.g. 
delirium, acute psychosis, advanced dementia, aphasia, clouded consciousness state) as well 
as palliative or terminally ill patients. We included patients suffering from mild dementia if a 
meaningful communication was possible (cf. Annex A2.6.).  
 Study Flow 
During a predefined period, the investigators (CK, NM, TS) and three additional trained clinical 
pharmacists met with every hospitalized patient on the included wards who met the inclusion 
criteria. They informed each patient orally and with an informational letter about the study. 
After giving informed consent, the patient received the DART and filled in the questionnaire 
independently, i.e. the investigator left the room or stayed in the room without giving any 
assistance in filling out the questionnaire. If a patient showed impaired manual skills, the 
investigator could assist with the writing. When finished, the investigator asked the patient 
five questions about the structure and content of the DART in order to see if the questionnaire 
was easy to understand and not too intrusive (cf. Annex A2.3.). Furthermore, the investigator 
interviewed the patient in detail with regard to the patient’s attitude towards health and 
medicine. Validated questionnaires were used to investigate compliance (Morisky Medication 
Adherence Scale – MMAS-8[177]), concerns and beliefs towards medicines (Beliefs about 
Medicines Questionnaire - BMQ[178]), and mental health (Micro Mental Test - MMT[179]). 
Participation in the study was voluntary. The patient could terminate the interview at any time 
without giving a reason. 
 
Pre-test 
With a first draft of the DART, we conducted a pre-test with five inpatients. The procedure 
followed the same study flow we determined for the validation study (see study flow). This 
pre-test with inpatients served as an opportunity to correct any remaining issues of 
comprehensibility or ambiguity. 
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Data Collection and Analysis 
We evaluated all data anonymously. In order to ensure traceability, we assigned each patient 
a unique identifying number coding for the particular hospital/ward/investigator/patient. All 
data were entered in a prepared case report form (cf. Annex A2.4.). The investigator CK 
provided written instructions for the completion of the CRF (cf. Annex A2.5.) 
We used the IBM SPSS Statistics Software, V 22 (IBM Corp., Armonk, NY, USA) for data analysis. 
We transferred all collected data in an SPSS table. A second investigator double-checked all 
data. In cases of ambiguity, we discussed the affected data with all authors. We evaluated 
sensitivity and specificity of each question of the DART by comparing the subjective answers 
in the DART with objective data from medical records (diagnosis, laboratory values, and 
medicines at entry) and answers from the MMAS-8[177], the BMQ[178] and the MMT[179]. 
Acceptance criteria for correlation of subjective and objective data were defined a priori (cf. 
table B2-1). We calculated the sensitivity and specificity for each question of the DART and 
added the prevalence of each risk factor (except questions number 8, 16, 17 and 18 (cf. figure 
B2-1). No objective measurement is possible or needed to correlate them). We calculated the 
chi-square-test or Fisher’s Exact Test, when appropriate and the phi-coefficient as a measure 
for the association of subjective with objective data. A value of p <0.05 was considered 
statistically significant. For our data sample, the phi-coefficient could range from 0 to +1, 
where 1 indicates perfect association, and 0 indicates no relationship. Missing data were 
excluded from analysis. 
 
Results 
Development of the questionnaire 
The first page of the DART consists of ten items concerning the presence of diseases and high-
risk medicines. The second page includes nine items reflecting the patient’s attitude towards 
his/her medicines and statements about medication management and handling difficulties (cf. 
figure B2-1). The ten non-patient individuals from the amateur test had no difficulties 
completing the questionnaire, and only minor adjustments in wording were necessary. 
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Figure B2-1: Drug Associated Risk Tool (DART), page 1of 2 
Legend: Detrusitol = Tolterodine (most used anticholinergic drug in Switzerland), Tryptizol & Limbitrol = 
Amitriptyline, Tofranil = Imipramine 
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Figure B2-1: Drug Associated Risk Tool (DART), page 2 of 2 
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Validation of the questionnaire 
The pre-test with five inpatients did not reveal any additional issues, and we decided to start 
the validation study without major changes. 
During ward visits, we approached 208 eligible patients. Out of them 165 (79.3%) consented 
to participate, and we were able to complete 164 patient interviews (cf. figure B2-2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B2-2: Flow chart of the validation study 
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The median age of 164 patients entering the validation study was 74 years with a minimum 
age of 20 and a maximum age of 95. Forty-nine percent of participants were female. The mean 
number of drugs per patient at time of admission was 4 and ranged from 0 to 19. Fifty-six 
(34%) patients came from the geriatric ward with a mean age of 81 (40-95) years and a mean 
number of drugs of 5 (0-19). Sixty-eight (42%) patients were from the medical ward with a 
mean age of 65 (20-91) years and a mean number of drugs of 3 (0-15) and 40 (24%) patients 
were orthopaedic patients with a median age of 67.5 (20-91) years and a mean number of 
drugs of 4 (0-10). 
 
After 51 interviews, we reduced the number of questions. We eliminated the questions about 
feasibility and understandability of the DART, because we had enough meaningful data with a 
clear conclusion. For the same reason, we stopped answering the Morisky and the BMQ 
questionnaire that we used for comparison with the answers from the DART. This allowed us 
to shorten the duration of the patient interview.  
On average, it took patients 7 minutes to complete the DART by themselves. None of the 
patients found any of the statements bothersome or too intrusive on his privacy. Ten out of 
51 patients showed some difficulties in completing the questionnaire, seven did not 
understand the wording of a statement and in three cases, data are missing. The DART 
questions reached an overall specificity of 0.95 (range: 0.82-1), whereas the overall sensitivity 
was 0.58 (range: 0.21-1). All questions (except statement number 9 about polypharmacy, the 
statements concerning the intake of Digoxin or anticholinergic drugs and statements 12-15 
about the BMQ) showed a significant correlation between the patient’s answers and the 
objective data. The extent of correlation varied a lot, the ϕ -coefficient showed a range from 
0.29 – 0.88. More details are shown in table B2-2. Regarding the intake of OTC drugs, eighty-
five patients (35%) affirmed, 103 (63%) patients denied, and three patients (2%) gave no 
answer. On the question “I feel well informed about my medication”, 85 patients (52%) 
answered with “strongly agree”, 45 (27%) agreed, 18 (11%) disagreed, three (2%) strongly 
disagreed and 13 patients (8%) gave no answer. Ten (6%) patients named difficulties with 
tablet-splitting, 17 (10%) mentioned swallowing difficulties, 5 (3%) patients affirmed 
difficulties with visual recognition and 122 (74%) said that they have no such problems. Fifteen 
(9%) answers were missing. One hundred and twenty five patients (74%) managed their 
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medication by themselves, 12 (7%) had a relative or a friend who did the management, 15 
(9%) patients named a home care person as their medication manager and 16 (10%) patients 
gave no answer. Sixteen (10%) of the patients indicated that they use an inhaler, 15 (9%) a 
transdermal therapeutic system, 18 (12%) a syringe for self-injection, 101 (62%) did not use 
any of these application forms and 20 (12%) gave no answer. 
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Table B2-1: Risk factors, their corresponding statement in the Drug Associated Risk Tool (DART) and criteria to evaluate correlation between the answers in the DART and 
objective data 
Risk factor Corresponding 
statement DART 
Acceptance criteria for correlation 
Language issues (e.g. migration background) 1 No comparison with objective data 
Polymorbidity: divided in subcategories 
- Renal impairment 
 
- Hepatic impairment 
 
- Chronic cardiac disease 
 
- Chronic respiratory disease 
- Diabetes 
- Cognitive impairment/dementia 
2 
 
3 
 
4 
 
5 
6 
7 
- Diagnosis of renal impairment AND/OR GRF<60ml/min for at least 3 
months [180]. 
- Diagnosis of hepatic impairment AND/OR chronic hepatitis AND/OR 
hepatic cirrhosis 
- Diagnosis of chronic cardiac disease (heart failure, coronary heart disease, 
arrhythmias) 
- Diagnosis of asthma or chronic obstructive pulmonary disease 
- Diagnosis of diabetes mellitus type 1 or 2 or diabetes caused by steroids 
- Diagnosis of cognitive impairment or dementia OR 25/30 points in the mini 
mental state examination (MMSE) [181] OR < 14/20 points in the Micro-
Mental-Test (MMT) [179] 
The patient takes medication(s) besides the prescribed ones 
 (e.g. over-the-counter, vitamin supplementation) 
8 No comparison with objective data possible 
Polypharmacy 9 The patient takes more than five medicines when admitted to the hospital 
Antiepileptic, anticoagulants, NSAIDs, non-steroidal 
antirheumatics, comb. of NSAID and anticoagulants, digoxin, 
corticosteroids, diuretics, tricyclic antidepressants, 
anticholinergic drugs, benzodiazepines, opiates/opioids, oral 
antidiabetics/insulin, medication with a narrow therapeutic 
range 
10 The drug is present on patients medication list at hospital admission 
Non-Adherence 11 < 8 points in the MMAS-8 questionnaire 
Earlier experience of ADRs 12-15 Negative total score in both - the statements 12-15 AND the BMQ 
OR a positive total score in both – the statements 12-15 AND the BMQ 
Missing information, partial knowledge of the patient, the 
patient does not understand the goal of the therapy 
16 No comparison with objective data needed.   
Impaired manual skills - causing handling difficulties 17 No comparison with objective data needed.   
Visual impairment / impaired eye-sight 17 No comparison with objective data needed.   
Difficult to handle medication 19 Medicines for parenteral, transdermal or inhalative application at time of hospital 
admission 
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Table B2-2: Calculated sensitivity and specificity of the single statements of the DART 
Legend: n.a. = not applicable; RF = risk factor, χ2: chi-square, ϕ: phi-coefficient 
 
Statements or questions 
of the DART 
Number of 
answers [n] 
Missing 
data 
True 
pos. 
False 
pos. 
True 
neg. 
False 
neg. 
Prevalence of 
the RF (%) 
Sensitivity Specificity χ2  
[P] 
ϕ (P) 
I am suffering from a chronic renal disease 162 2 9 3 127 23 20 0.28 0.98 < 0.001 0.39 (<0.001) 
I am suffering from a chronic hepatic disease 161 3 4 1 148 8 07 0.33 0.99 < 0.001 0.50 (< 0.001) 
I am suffering from a chronic cardiac disease 159 5 26 3 96 34 38 0.43 0.96 < 0.001 0.51 (< 0.001) 
I am suffering from a chronic respiratory 
disease 
157 7 14 1 129 13 17 0.52 0.99 < 0.001 0.72 (< 0.001) 
I am suffering from diabetes 158 6 23 0 129 6 18 0.79 1.00 < 0.001 0.87 (< 0.001) 
I have troubles remembering things or tend 
to forget things 
157 7 9 26 116 6 10 0.60 0.82 < 0.001 0.29 (< 0.001) 
I take more than 5 drugs every day, 
prescribed by my physician 
144 20 10 12 84 38 33 0.21 0.88 0.190 0.11 (0.190) 
Sleeping pills 147 17 15 10 121 1 11 0.93 0.92 < 0.001 0.71 (<0.001) 
Cortisone or other steroids 149 15 11 2 129 7 12 0.61 0.98 < 0.001 0.69 (<0.001) 
Antiepileptic drugs 149 15 0 0 149 0 00 n.a. 1.00 n.a. n.a. 
Oral anticoagulants 149 15 21 5 123 0 14 1.00 0.96 < 0.001 0.88 (< 0.001) 
Tricyclic antidepressants 149 15 2 2 145 0 01 1.00 0.99 0.001 0.70 (< 0.001) 
Drugs for rheumatism/inflammation 149 15 7 18 120 4 07 0.64 0.87 < 0.001 0.35 (< 0.001) 
Drugs for drainage (diuretics) 149 15 26 9 89 25 34 0.51 0.91 < 0.001 0.47 (< 0.001) 
Digoxin 149 15 1 0 147 1 01 0.50 1.00 0.013 0.71 ( <0.001) 
Anticholinergic drugs 149 15 1 0 146 2 02 0.33 1.00 0.020 0.57 (<0.001) 
Insulin/drugs used in diabetes 148 16 16 2 127 3 13 0.84 0.98 < 0.001 0.85 (< 0.001) 
Do you ever forget to take your medicine? 61 103 11 0 28 22 54 0.33 1.00 < 0.001 0.61 (< 0.001) 
BMQ 54 110 39 8 3 4 20 0.27 0.91 0.036 0.69 (0.036) 
I use some of these application forms: spray 
for inhalation, skin patch, syringe for self-
injection 
129 35 27 12 84 6 26 0.82 0.88 < 0.001 0.66 (<0.001) 
Mean value        0.58 0.95   
Range        0.21-1 0.82-1   
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Discussion 
With the present study, we intended to create an easy-to-use and reliable screening tool to 
identify patients who are at increased risk for DRPs. The application of such a tool has the 
potential to support the healthcare professionals in choosing the patients who would benefit 
the most of intensified pharmaceutical care. In our opinion, a patient-self-assessment tool is 
not only a time- and resource-saving approach for healthcare professionals, but also allows by 
the involvement of the patient, to assess risks for DRPs in a more comprehensive way.  
As a basis for the tool, we used risk factors for the development of DRPs evaluated in a former 
project where we combined a literature search with the statements of an expert panel [176]. 
As far as we know, this approach has not been adopted previously in this area of research.  
The Drug Associated Risk Tool (DART) showed a good acceptability and feasibility. The patients 
completed the self-assessment quickly and indicated no major difficulties with understanding 
the content of the questionnaire. The 48 patients (23%) who refused to participate were either 
not interested in participating or felt too tired to follow an interview.  
All statements of the DART showed a high specificity (mean value: 0.95, range 0.82 – 1.00). 
Thus, we can exclude false positive cases with a high probability. The sensitivity of the 
statements, however, was lower and showed more variability (mean value: 0.58, range 0.21 – 
1.00). In general, the sensitivity turned out to be higher in statements addressing conditions 
that require regular disease control and daily attention to self-care and drug management. 
Drugs requiring a high level of self-management showed the highest sensitivity (e.g. oral 
anticoagulants, insulin and oral antidiabetics). We assume the more symptoms they suffer 
from, the higher is the patients’ awareness about their disease(s).  
Several factors might have influenced the sensitivity and the correlation. First, the defined 
criteria for correlation (cf. table B2-1) served as a basis for the validation of the questionnaire. 
Depending on how we defined the criteria, we reached a certain degree of correlation 
between patients’ answers and the objective data. After a first validation of the DART, a 
revision of certain criteria could be useful. As an example: the sensitivity for the question on 
adherence was low. The original MMAS-8 [177] questionnaire defines high adherence with a 
score of 8 on the scale, moderate adherence with a score of 6 to < 8 and low adherence with 
a score of < 6. In our acceptance criteria, we defined a score beyond eight points as “non-
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adherent”. If we were to change our criteria and define only a score beyond 6 as “non-
adherent”, our sensitivity would increase from 0.33 to 0.42, but the specificity would decrease 
from 1 to 0.88. Second, we evaluated the sensitivity and specificity of each question by 
comparing the subjective answers in the DART with objective data from medical records. 
Literature shows that medication histories at the time of hospital admission are often 
erroneous or incomplete [182], which might have influenced our results. Especially the 
statement “I take more than 5 drugs every day, prescribed by my physician”, showed 
surprisingly weak correlation between subjective patient answers and objective medical data. 
Lau et al. [183] stated that regarding at the medication history in the hospital medical record, 
25% of the prescription drugs in use are not recorded and 61% of all patients have one or more 
drugs not registered. Bedell et al. [184] evaluated the discrepancies between what physicians 
prescribe and what patients report they actually take. They showed, that discrepancies 
between recorded and reported medication are common. Half of the discrepancies (51%) 
result from patients taking medications that were not recorded. One third of the discrepancies 
involved over-the-counter drugs or herbal therapies. A more reliable medical record including 
an accurate medication list will be necessary for further research in order to avoid conclusions 
derived from incomplete medical data. Thirdly, patients stated that they had no problems with 
filling in the DART; however, we noticed some problems with their understanding of the word 
“chronic”. Some rephrasing will be necessary in order to clarify statements about chronic 
conditions. 
Finally, the low prevalence of some risk factors is a limitation of our results. Some risk factors 
showed such a low prevalence (e.g. antiepileptic drugs, tricyclic antidepressants, digoxin and 
anticholinergic drugs) that a clear conclusion concerning the validity of these questions in the 
DART is not possible. Larger studies will be necessary to strengthen our findings. A potential 
limitation to our study might also be the patient selection. Patients who refused to participate 
may have been individuals with less knowledge about their illness and therapy.  
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Conclusion 
The new DART self-assessment questionnaire showed a satisfying feasibility and reliability. 
Despite some low sensitivity values, this questionnaire seems to be applicable to patients in a 
hospital setting. Patients may be a valuable, but often neglected source of information. Asking 
them about their conditions, their medications and related concerns and problems can 
facilitate getting a first, but broad picture of the risk for DRPs and possible pharmaceutical 
needs. Compared to gathering all the relevant data from case notes, electronic patient files 
and other sources, a self-assessment questionnaire seems to be a quick and easy method. To 
strengthen the reliability of the DART some questions should be rephrased and risk factors 
with a very low prevalence should be validated in a more specific population.   
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ABSTRACT 
Background: Clinical pharmacy services in hospitals have been shown to increase patient 
safety by reducing drug-related problems (DRPs). However, restricted resources and 
capacities limit pharmacists’ activities. A tool to assess patients at risk from DRPs may serve 
as a successful approach to target pharmaceutical activities for those patients who benefit the 
most. Despite development of numerous risk assessment tools, a comprehensive overview is 
missing.  
Objective: To create a structured overview of existing tools for the assessment of a patients’ 
risk of experiencing DRPs.  
Methods: We conducted a non-systematic literature search with a clear search strategy using 
Pubmed. The tools were sorted by year and the following properties were extracted and 
mapped in a structured way: information on the content, development method, and extent 
of validation. 
Results: The literature search resulted in 15 risk assessment tools. Seven tools (47%) focused 
on elderly patients and eight tools (53%) included adult patients in general. Nine tools (60%) 
were developed for use in primary care and six (40%) for use in secondary care. Seven tools 
(47%) were designed for self-assessment. The development of the tools varied significantly. 
One tool (7%) was developed by using a literature search, three tools (20%) based on a 
statistical analysis and other 3 tools (20%) used an orientation on existing tools who served as 
basis for the development of the new tool. Three tools (20%) combined a literature search 
with the consultation of healthcare experts, 1 tool (7%) combined the literature search and 
the orientation on unpublished screening tools, 1 tool (7%) used a statistical analysis of 
variables and supplemented it with data from the literature and one tool (7%) combined 
statistical analysis with expert opinions. Two tools (13%) provided no clear information on 
their development. 
Discussion: This overview revealed an increased level of activity in the field of risk-assessment 
during the last few years. Published assessment tools are very heterogeneous and differ in 
structure, content, targeted patient group, setting for application, selected outcomes and 
extent of validation. Our comprehensive mapping may serve as a summary to assist readers 
in choosing a tool, either for research purposes or for use in daily practice. 
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INTRODUCTION 
Drug-related problems (DRPs), which have been defined as “an event or circumstance 
involving drug therapy that actually or potentially interferes with desired health 
outcomes”[4], include medication errors (MEs), adverse drug events (ADEs) and adverse drug 
reactions (ADRs). An ME is “any preventable event that may cause or lead to inappropriate 
medication use or patient harm while the medication is in the control of the healthcare 
professional, patient or consumer”[5]. An ADE can be defined as “an injury—whether or not 
causally related to the use of a drug”[6]. ADRs include “any response to a drug which is noxious 
and unintended, and which occurs at doses normally used in humans for prophylaxis, 
diagnosis or therapy of diseases, or for the modification of physiological functions”[7]. DRPs 
are very common in primary and secondary care leading to patient harm and increased 
healthcare costs [16, 18, 185, 186].  
Clinical pharmacy services in hospitals have been shown to increase patient safety by reducing 
MEs, ADEs and ADRs. They increase medication appropriateness, improve patients’ 
knowledge about drug therapy and adherence, and reduce the length of hospital stay [54]. 
However, with pharmacists’ limited resources and capacities, it is important to identify which 
patients would benefit the most from clinical pharmacists’ activities. An obvious approach is 
to focus on the patients who are at the highest risk of experiencing DRPs. 
During recent years, attempts have been made to determine risk factors (RFs), which may 
determine the occurrence of DRPs. The most prevalent RF is polypharmacy [16, 141-147], 
showing the strongest association with adverse outcomes, whereby the definition of 
polypharmacy varies between the intake of “more than 4” to “8 drugs and more”. Besides 
polypharmacy, polymorbidity [141, 145], renal impairment [16, 141, 145, 146] and 
dementia/impaired cognition [141, 147] are prevalent RFs in many studies. Focusing on drugs, 
most publications highlight oral anticoagulants [16, 141, 143, 146, 148], diuretics [16, 146, 
148], non-steroidal anti-rheumatics [141, 148] and antidiabetics [141, 146] as medication with 
the highest risk of causing harm. Research following a qualitative approach revealed 
communication failures and knowledge gaps, underpinned by a variety of contributing factors, 
including time and workload pressures and problems with computer system design, as major 
causes for drug-related hospitalisations [148].  
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A tool for a fast and reliable identification of patients, showing such RFs, may be a successful 
approach to target clinical pharmacy activities and therefore save resources and increase 
efficiency. Different tools to assess patients at risk for DRPs have already been developed and 
published. These instruments differ widely from each other depending on the outcomes they 
focus on (e.g. DRPs, ADRs), the setting for which they were developed (e.g. primary or 
secondary care), the patient group they target (e.g. elderly patients, all age groups) and their 
method of application (e.g. self-assessment). A comprehensive overview has been missing. 
The objective of this study was to provide a literature search to create a comprehensive and 
structured overview of existing risk assessments. A mapping exercise was undertaken to give 
an orientation on content, development method and potential validation of the tools. 
 
METHODS 
Literature search and mapping 
We conducted a non-systematic literature search with a clear search strategy on Pubmed by 
using the following MeSH terms: “Drug-related side effects and adverse reactions”, 
“medication errors”, “risk”, “risk assessment” and the following search terms: “risk score”, 
“patient safety”, “risk management”, “pharmacist”, “tool”. The absence of a MeSH term for 
DRPS limited a precise search strategy. “Drug-related side effects and adverse reactions” 
served as the closest possible approach, including ADRs and ADEs. The database search was 
completed with a manual search from the reference list of included articles. We limited our 
search to studies in adults. Articles must have been published in English or German.  
Title and abstracts were screened for relevance. They needed to contain the term “tool” or 
similar terms with similar meanings like “instrument”, “assessment”, “questionnaire” AND 
“drug-related problems” or similar terms like “medication-related problems”, “adverse drug 
events”, “adverse drug reactions”. Studies which focused on RFs for the occurrence of DRPs 
without the description of a screening instrument where excluded, as well as tools targeting 
children, medication review techniques which did not use a tool, risk screening which did not 
focus on DRPs/circumstances and general guidelines/recommendations or educational 
interventions to assess patients at risk for DRPs.  
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The reviewer (CPK) screened articles for eligibility. Each article showing uncertainty regarding 
inclusion or exclusion criteria was discussed with two of the authors (CPK, MLL). We mapped 
the tools in a structured way by describing briefly their content, development method and 
validation steps. We sorted the tools by year to show the progress in the topic of risk 
assessment.  
 
RESULTS 
The literature search resulted in 15 risk assessment tools (cf. table B3-1). Eight tools (53%) 
were developed for the detection of risk for DRPs (also named by researchers as medication-
related problems), 3 tools (20%) screened for ADRs and other tools named other outcomes 
similar to DRPs, such as “drug therapy problems”, “medication misadventure”, “difficulties in 
managing medication” and “risk for rehospitalisation”. The term “risk for rehospitalisation” 
seemed unsuitable for our inclusion criteria. However, the focus on patient’s drug therapy was 
described in the abstract of the tool, which justified its inclusion. Seven tools (47%) focused 
on elderly patients and eight tools (53%) included adult patients in general. Nine tools (60%) 
were developed for use in primary care and six (40%) for use in secondary care. Seven tools 
(47%) were designed as self-assessment. The development of the tools varied significantly and 
included a literature search (1 tool, 7%), statistical analysis of variables (3 tools, 20%), or the 
orientation on existing tools who served as basis for the development of the new tool (3 tools, 
20%). Three tools (20%) combined a literature search with the consultation of healthcare 
experts, 1 tool (7%) based its development on data from literature and unpublished screening 
tools, 1 tool (7%) used a statistical analysis of variables and supplemented it with data from 
the literature and one tool (7%) combined statistical analysis with expert opinions. Two tools 
(13%) provided no clear information on their development. 
 
DISSCUSSION 
Our overview showed an increasing activity in the field of risk-assessments for DRPs. Seven of 
15 tools had been published in the last two years. Canada and the UK were pioneers, with 
different European countries following. Pharmacists have been actively involved in the 
development of every tool, what shows their increasing presence and importance as one of 
the stakeholders in the area of medication safety. Almost half of the tools focused on elderly 
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patients because geriatric patients usually present with multiple morbidities and complex 
pharmacotherapy which makes them susceptible for adverse outcomes. The usability of tools 
for the identification of patients at risk for ADRs seemed questionable, as ADRs are, according 
to our definition, not preventable. Sometimes the definition for an ADR corresponded more 
to an ADE, which in some cases led us to believe that researchers may have mixed up ADRs 
with ADEs. 
Compared to older tools, recently published instruments were often designed for the 
implementation in an electronic system in order to screen electronic patient records for the 
presence of RFs. Very comprehensive questionnaires like the tool from Pit et al. [159] may be 
less applicable nowadays due to the presence of limited resources. An electronic tool has the 
advantage of fast and easy screening, reducing healthcare professional time expenditure. 
Many tools lack proper validation. They have been validated regarding feasibility and 
acceptability, but a proven association with clinical outcomes is often missing. This may be 
because of the effort in time and resources needed to conduct a proper validation study.  
Limitations 
The literature search was restricted to articles published in English and German; criteria 
published in other languages were not included because analysing and mapping the tools 
required a complete understanding of the text. We did not conduct a fully systematic 
literature search. Keywords used in title and abstracts, were heterogeneous what made the 
development of a comprehensive search strategy difficult.   
 
CONCLUSION 
The literature search revealed 15 screening tools for the assessment of patients at risk for 
DRPs. All tools focus on the occurrence of problems with patient’s medication but are very 
heterogeneous with respect to content and selected outcomes. Most of the tools showed no 
complete validation. Comprehensive, but user-friendly tools with a proven association with 
well-selected outcomes are needed to enable pharmacists to target their clinical activities in 
the most efficient way. 
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Table B3-1: Tools for the assessment of patients at risk for DRPS (last updated: 08/2015) 
Author 
[Year] 
Country Title of the publication/ Description of the tool Development Validation 
Barenholtz 
Levy et al. 
[2003] 
[117] 
Canada Self-Administered Medication-Risk 
Questionnaire in an Elderly Population 
A 10-item self-administered questionnaire for 
the use by elderly patients (≥60 years) to 
identify who is at increased risk of potentially 
experiencing a medication-related problem 
(MRP). 
 
 
The 10 items selected for inclusion in the questionnaire 
were based on published literature [128, 187] and 
unpublished screening tools obtained through colleagues 
of the researchers. Clarity of the questionnaire was pilot-
tested in 10 patients, with wording adjusted for the final 
version. 
Validated concerning 
acceptability, feasibility, inter-
rater and test-retest reliability, 
internal consistency, verification 
of the accuracy of the patient 
self-reports, applicability of the 
tool (prospective validity) 
Fuller et al. 
[2005] 
[154] 
UK Validating a self-medication risk assessment 
instrument 
A 7-item self-medication risk assessment who 
should allow nurses, pharmacists and physicians 
to screen elderly people, who live alone, for 
difficulties in the management of their 
medication.  
 
 
 
No detailed explanation concerning the development of 
the tool available.  
Validated concerning internal 
consistency, intra-and interrater 
reliability 
Gordon et 
al. [2005] 
[155] 
UK The development and validation of a screening 
tool for the identification of patients 
experiencing medication-related problems 
A patient interview, divided into five sections 
with questions regarding their use of medicines 
and medical services and focused on patients in 
a primary care setting, using drugs for 
cardiovascular diseases. 
 
 
 
The tool was developed based on a literature review. No 
further details on the development were described. 
Partially validated by assessing 
the practicability and sensitivity 
of the tool. 
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Author 
[Year] 
Country Title of the publication/ Description of the tool Development Validation 
Langford et 
al. [2006] 
[188] 
Canada Implementation of a Self-Administered 
Questionnaire to Identify Patients at Risk for 
Medication-Related Problems in a Family 
Health Center 
A 5 item self-administered questionnaire to 
identify patients at risk for medication-related 
problems in primary care. 
 
The questionnaire was developed out of the already 
existing and validated questionnaire from Barenholtz 
Levy [117].  
Validated concerning feasibility. A 
lager validation study is planned.  
Pit et al. 
[2008] 
[159] 
Australia Prevalence of self-reported risk factors for 
medication misadventure among older people 
in general practice 
A 31-item medication risk self-assessment form 
in order to find patients in primary care who 
may benefit from a medication review.  
 
 
The risk assessment is based on a list of “triggers” 
identifying patients for whom a medication review might 
be beneficial, published by the National Prescribing 
Service [189]. A first draft of the tool was discussed with 
an expert panel, followed by two pre-tests and a pilot 
test with patients and healthcare professional in the 
primary care area.  
Only validated for acceptability 
and feasibility 
Roten et al. 
[2010] 
[158] 
CH An electronic screening of medical records to 
detect inpatients at risk of drug-related 
problems 
An electronic screening tool for clinical 
pharmacists, which screens the medical records 
of inpatients and helps detecting patients at risk 
for DRPs in preparation for the ward round. 
 
 
Electronical queries as basis for the tool were formulated 
based on a literature review, experience of clinical 
pharmacists, a list of queries used at a hospital in Boston 
USA (personal contact), and the programming feasibility. 
Prospectively validated against 
standard of care (CP doing 
medication review on the ward). 
Calculation of sensitivity and 
specificity of the tool 
Onder et al. 
[2010] 
[145] 
Italy Development and Validation of a Score to 
Assess Risk of Adverse Drug Reactions Among 
In-Hospital Patients 65 Years or Older 
A nine-item GerontoNet ADR Score 
 
 
 
 
A physician collected all baseline characteristics of the 
patients (age, gender, diagnosis, drug history,…) by 
questionnaire. In a prospective study all ADRs where 
documented. All patient variables where statistically 
compared according to the presence of ADRs. Variables 
with a strong association with an ADR where included in 
the final risk score. The study was supplemented with 
data from medical literature.  
Validated concerning the 
predictive validity of the score 
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Author 
[Year] 
Country Title of the publication/ Description of the tool Development Validation 
Rovers et 
al. [2012] 
[157] 
USA Self-assessment tool for screening patients at 
risk for drug therapy problems.  
A 12-item tool for the application in the primary 
care setting. 
 
Development method not provided No clear information provided.  
Dimitrov et 
al. [2014] 
[190] 
Finland Content validation of a tool for assessing risks 
for DRPs to be used by practical nurses caring 
for home-dwelling clients aged ≥ 65 years: a 
Delphi survey 
18-item tool for assessing risks for DRPs  
 
The tool was developed based on two systematic 
literature reviews and the clinical expertise of the 
research group. Content validity was determined by a 
three-round Delphi survey involving a panel of 18 experts 
in geriatric care and pharmacotherapy. 
Validated concerning content 
validity and feasibility. Pending 
predictive validity 
Makowsky 
et al[2014] 
[191] 
Canada Feasibility of a self-administered survey to 
identify primary care patients at risk of 
medication-related problems 
A 10-item self-administered survey  
 
The paper survey was developed out of two already 
existing and validated questionnaires: the 10-item MRP 
questionnaire by Barenholtz Levy [117], and the modified 
five-item questionnaire by Langford et al [188]. 
Only validated concerning 
feasibility 
Sharif  
et al. 
[2014] 
[173] 
United 
Arab. 
Emirates 
Development of an Adverse Drug Reaction Risk 
Assessment Score among Hospitalized Patients 
with Chronic Kidney Disease  
An assessment score, using 7 evaluated RFs to 
predict the risk for an ADR in hospitalized 
patients with chronic kidney disease 
 
Development of an electronic prediction model, based on 
statistic evaluations of associations between 
prospectively collected patient characteristics with the 
occurrence of an ADR. 
Only validated concerning the 
reliability of the electronic 
generation of risk scores 
Tangiisuran 
et al. 
[2014]  
[192] 
UK Development and Validation of a Risk Model 
for Predicting ADRs in Older People during 
Hospital Stay: Brighton Adverse Drug Reactions 
Risk (BADRI) Model  
A risk model, based on 5 clinical variables. 
 
 
 
 
 
A prospective study where collected patient data were 
statistically correlated with assessed ADRs. Variables that 
were identified in other studies as being important 
predictors of ADR were also included in the statistical 
analysis. The five final variables were chosen using a 
stepwise statistic selection procedure. 
Externally validated concerning 
predictive validity (sensitivity and 
specificity) 
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Author 
[Year] 
Country Title of the publication/ Description of the tool Development Validation 
Urbina et 
al. [2014] 
[175] 
Spain Design of a score to identify hospitalized 
patients at risk of drug-related problems 
A score to identify hospitalized patients at risk 
of DRPs. 
 
 
 
 
 
A prospective observational study. Patients’ baseline 
characteristics and data on diagnosis and drug history 
were gathered at time of admission. A statistical analysis 
of the data was performed to confirm or disconfirm the 
association between the presence of DRPs at admission 
with respect to each of the patient variables analysed. 
Variables with the highest sensitivity and specificity were 
selected for the score, according to the method of Onder 
et al. [145] 
 
Prospectively validated in a 
cohort of patients at the time of 
admission. 
Alassaad et 
al. [2015] 
[193] 
Sweden A tool for prediction of risk of rehospitalisation 
and mortality in the hospitalised elderly: 
secondary analysis of clinical trial data. 
A 7 item score, the “80+ score”, for the 
prediction of the risk of rehospitalisation and 
mortality in the hospitalized elderly, aged 80 
years and older 
 
Patient baseline characteristics were used from a 
randomised controlled trial (RCT) investigating the effects 
of a comprehensive clinical pharmacist intervention. 
Potential risk factors were selected based on a 
combination of clinical judgement and statistical 
properties of the variables. Selected data where 
statistically analysed for association with the defined 
outcomes “time to rehospitalisation” or “death”.  
 
Only internally validated, pending 
validation in an independent 
cohort 
Snyder et 
al. 
[2015] 
[194] 
USA Utility of a brief screening tool for medication-
related problems  
A 9-item screening tool for medication-related 
problems 
 
The questionnaire was developed out of items from an 
already existing questionnaire the” Blalock’s Drug 
Therapy Concerns Questionnaire (DTC)” [195] found by 
the authors in an earlier literature search. . 
Validated concerning reliability 
and predictive validity (sensitivity 
and specificity) 
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General discussion and conclusions 
The nature of DRPs has been investigated in numerous research projects over the last thirty 
years. DRPs are prevalent and a major problem for in-and hospital outpatients. Various 
attempts, like the implementation of clinical pharmacists for intensified patient care, have 
been described as effective in reducing DRPs and in consequences adverse health outcomes. 
Criteria to assess the appropriateness of prescriptions can serve as a helpful guideline to 
improve a patient’s pharmacotherapy in daily practice. This thesis developed a structured 
compilation of published criteria (project A) with the aim of assisting physicians and 
pharmacists to choose the most suitable tool. Restricted resources limit an extended 
implementation of clinical pharmacy services. Identifying those patients who show the highest 
risk for developing of DRPs would allow clinical pharmacists to increase their efficiency and 
save resources by targeting their activities. To realize this idea we identified in the second part 
of this thesis (project B) risk factors (RFs) for the occurrence of DRPs, translated them into a 
self-assessment tool for the identification of patients at risk for DRPs and validated the tool 
for its usability in daily practice. 
In project A we provided a comprehensive overview of published criteria for the assessment 
of inappropriate prescribing (IP). IP is a significant public health problem, especially in the 
elderly, resulting in increased morbidity, mortality and use of healthcare resources [32]. As 
the name indicates, IP mainly results from poor choice of medication by the prescriber. A tool, 
supporting the prescriber’s clinical judgement in drug selection should theoretically reduce IP 
[196].  
In our systematic literature research, we found 46 assessment tools, which indicated that the 
topic of IP is of great interest. The question arises as to which tool should be preferred? As we 
concluded, the ideal tool to assess the appropriateness of drug prescriptions should: 
 cover all aspects of appropriateness (efficacy, safety, cost-effectiveness and patients’ 
preferences) 
 be developed using evidence-based methods 
 show significant correlation between the degree of inappropriateness and clinical 
outcomes 
 be applicable not only in research conditions but also in daily healthcare practice 
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Mahony and Gallagher [196] further proposed that there should be: 
 generalizability for the global community of physicians and pharmacists  
 quick application and a clear organization on the basis of physiological systems 
 the ability to interface with electronic patient records 
None of the listed tools fulfilled all of the abovementioned requirements. The mapped tools 
differed widely from each other concerning structure, complexity and degree of 
comprehensiveness. Our mapping enabled an overview and orientation and may help as a 
decision aid, but does not provide an answer as to which tool might be “the best one”.  
When thinking about choosing a tool, users should be aware that the recommendations for IP 
vary depending upon the targeted patient group and the country in which the tool has been 
developed. It might be advisable for prescribers to choose a tool, developed in their own 
country, as these tools are usually adapted for nationally approved medicines and prescribing 
standards. The selection of a tool, which is regularly updated is preferred. The 
comprehensiveness, especially of explicit tools is a limitation of their use in daily practice. 
Implementing an explicit tool in an electronic system might be beneficial in terms of time, but 
poses a risk of excessively alerting physicians, who may ignore them. Further, when using 
these tools, it is important to keep in mind that “inappropriate” is not “contraindicated”. A 
drug, which is inappropriate for a patient may still be the best available option. 
Prescribers have to keep in mind that the degree of comprehensiveness and complexity gives 
no information about the extent of its association with positive or negative outcomes. There 
is a need for well-structured case-control studies to demonstrate that the application of IP-
assessment tools improves clinical outcomes. Existing indicators of preventable drug-related 
morbidity (e.g. [197], [198]) should be considered when conducting validation studies. 
Examples for such indicators are hyper - or hypokalemia, fall or fracture, gastrointestinal 
bleeding and digoxin toxicity. Of course there are many more. As we described in our project, 
the effect of the application of assessment criteria on health outcomes and healthcare costs 
still remains unclear and needs to be evaluated for most of the described tools. 
 
 
 General discussion and conclusions  
PhD Thesis Carole Kaufmann 118 
The topic of appropriate prescribing remains complex, time-consuming and requires clinical 
expertise. It is advisable that the responsibility for appropriate prescribing no longer falls 
solely on the shoulders of physician-prescribers. Rather the responsibility should be shared 
with all healthcare professionals in order to provide the most appropriate care to patients 
[46]. 
 
In project B we developed an tool to assess patients at risk for the development of DRPs in 
order to target clinical pharmacy activities. We evaluated risk factors (RFs) for the occurrence 
of DRPs (project B1), compiled and validated a risk assessment questionnaire, the Drug 
Associated Risk Tool (DART) out of these RFs (project B2) and conducted an literature search 
to identify current efforts in the field of risk assessment for DRPs (overview B3). 
For the assessment of RFs in project B1 we combined professional experience and knowledge 
of healthcare providers with a systematic literature search. This may serve as a valuable 
method to obtain an accurate representation of the real-life situation in the Swiss healthcare 
setting.  
We used the NGT as a method for eliciting RFs for the occurrence of DRPs. The systematic 
approach of this consensus technique provides more evidence based results than an 
unstructured expert meeting [151]. The involvement of all relevant stakeholders of the entire 
medication process in the expert panel enabled us to cover a great area of knowledge and 
expertise. We chose experts carefully to minimize psychosocial biases as described by Pagliari 
et al [172]. We followed recommendations from the literature [172] and tried to control these 
psychosocial influences as follows: 
 We selected a small sample size of ten experts, as endorsed by the literature. Larger 
groups may lack cohesiveness and be difficult for the investigator to lead.  
 We invited at least two stakeholders of the same working field.  
 We invited, where possible, experts from different geographic areas with no or only few 
direct professional contact. Therefore, the different hierarchical levels were within 
different institutions and the participants were not directly dependent from each other.  
 We assigned each expert a place in order to avoid grouping of friends or panelists of the 
same profession.  
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 We started with an introduction in the topic with the aim to bring the entire panels’ 
knowledge about DRPs to the same level.  
 We tried to ensure the participation of every expert in the discussion and that the 
contributions were equal.  
 We placed the first discussion round after the first rating of the collected RFs in order to 
avoid panelists being influenced before their rating occured. 
The NGT proved to be successful. The panellists were highly motivated and discussed in an 
engaging and informative way. They appreciated the interdisciplinary exchange and found 
that it would be worthwhile to conduct such discussion rounds more frequently. 
The literature search supported the findings from the NGT. Most of the RFs that were 
prevalent in the literature were mentioned by experts. This fact confirmed the ability to 
reproduce evidence based information with a carefully planned NGT. In addition, the 
literature revealed specific high-risk drugs. In the NGT we might have set the focus 
inadvertently on patient-specific RFs, which probably turned the focus away from single high 
risk drugs. The experts focused on patient characteristics and named only a few drugs, but 
important ones, like “anticoagluants”, “diuretics”, “Non-steroidal antirheumatics” and 
“anticholinergics” which are known for their high potential to cause harm. Depending on the 
accuracy of the literature search, one can find almost every drug associated with the risk for 
the occurrence of DRPs. Not all of them seem to be clinically relevant, not surprisingly that 
experts did not mention every drug. In contrast, experts mentioned many process-associated 
RFs rarely described in the literature. They highlighted the important role of seamless care 
issues for the occurrence of DRPs in their daily life. Therefore, the use of a NGT proved a 
valuable source of information for us by providing a considerable number of RFs rarely 
mentioned in the literature, but important for healthcare providers in their daily practice. The 
fact that we needed to exclude seamless care issues is a pity because the panelists attributed 
them with a high importance. We considered seamless care issues not to be individual risk 
factors but instead reflect system failures; they are, therefore, not assessable for an individual 
patient. However, we recognized them as important RFs for the occurrence of DRPs in general 
and concluded that there is a need for improvement in this area. 
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We finally conducted the Delphi technique with 42 RFs with the aim of letting experts reassess 
the importance of every RFs concerning the occurrence of DRPs, including RFs from the 
literature search. We chose the same ten experts for the Delphi questionnaire that took part 
in the NGT because they were already familiar with the topic. We conducted only two Delphi 
rounds. We could see the consensus-forming processes by summing up the IQRs that we 
calculated for both rounds. As our Delphi technique took part in the form of an online 
questionnaire, we had no problems with the occurrence of psychosocial biases. Participants 
could fill in the survey anonymously and in an environment where they feel comfortable  
A lot of RFs mentioned by the experts were also mentioned in scientific publications. As an 
example, Gordon et al. developed their risk assessment tool based “only” on a literature 
review [155] and showed similar RFs to us. 
Inclusion of an expert panel in the process of identification of RFs was beneficial because: 
 The experts identified RFs that were relevant in the Swiss health system, as most studies 
on the topic of risk assessment were conducted outside Switzerland. 
 The experts assessed the relevance of each of the identified RF with respect to their 
experiences in daily practice.  
 The experts mentioned very patient specific RFs like impaired manual skills, visual 
impairment and missing information/understanding of the therapy. These RFs were not 
or less prevalent in our results of the literature search which could lead to the assumption 
that they were also less relevant for the occurrence of DRPs. The fact, that the experts 
highlighted their relevance showed their importance in daily practice. 
 The expert gave valuable inputs concerning application of the tool (patient self-
assessment) 
With the Delphi questionnaire, following the NGT and the literature search, we were able to 
focus on 27 RFs judged by the experts as very important or important for the occurrence of 
DRPs, which we could use as basis for the development of our risk assessment tool.  
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In project B2 we developed a risk assessment tool and validated it concerning feasibility, 
acceptability and reliability of patients answers. RFs from project B1 served as a basis for the 
questionnaire. To see what already has been done in the field of DRP risk assessment, we 
searched literature and created an overview of already published risk assessment tools 
(overview B3).  
We developed the Drug Associated Risk Tool (DART) in the form of a self-assessment to be 
filled out by the patient himself. A patient-self-assessment tool is not only a time - and 
resource-saving approach for healthcare professionals but also allows, by the involvement of 
the patient, an assessment of risks for DRPs in a more comprehensive way. Vincent et al. [153] 
supported healthcare providers to recognize and encourage the active role of the patient in 
their care and not to think of them in a passive way. Our final list of RFs contained factors like 
“Missing information, half-knowledge of the patient, the patient does not understand the goal 
of the therapy”, “Self-medication with non-prescribed medicines”, “Impaired manual skills” 
and “Visual impairment”, judged by the experts as “very important” or “important” for the 
occurrence of DRPs. It is obvious that we received the most accurate answers to these 
questions by asking the patients themselves.  
We did not limit the application of the DART to specific adults. With the patient recruitment 
on different hospital wards, we were able to cover a broad, representative sample of patients. 
The orthopedic ward served as a source for younger patients generally with no chronic 
conditions and therefore no or only few RFs. These patients were suitable for the evaluation 
of the specificity of our statements. In contrast, geriatric and medical patients tended to have 
different diseases and treatments and were important for the evaluation of the sensitivity of 
the DART. With this approach, we reached a population that was very heterogeneous varying 
in age (range: 20-89 years) as well as the number of medications at admission (range: 0-1). All 
chronic diseases we asked for in the DART were prevalent among our patients. The prevalence 
of swallowing difficulties was similar to findings from another Swiss study (10%) [199]. The 
prevalence of patients showing problems with the splitting of their tablets was unexpectedly 
low at 7%. Data from a German study showed much higher values [200]. An explanation could 
be the inclusion of many younger patients with no or only few medicines. On the other hand, 
the geriatric patients frequently indicated that their relatives or a care person prepare their 
drug therapy and do split the tablets for the patients.  
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We found the DART to be acceptable to the participants and feasible for self-administration. 
The DART showed an overall sensitivity of 58% and an overall specificity of 95%. In comparison 
with risk assessment tools from our literature search (overview B3), indicating sensitivity and 
specificity values, the DART reached a satisfying high specificity and a slightly lower sensitivity. 
Gordons screening tool [155] showed a sensitivity of 81% and a specificity of 87%. Onder et 
al. [145] evaluated a sensitivity of 68% and a specificity of 65% for their tool and Roten et al. 
[158] achieved a sensitivity of 85% and a specificity of 60%. The DART is the only self-
assessment in this list, which might have contributed to its lower sensitivity. Roten et al. [158] 
developed an electronic screening, whereby he formulated the aim to reach a sensitivity of at 
least 80%. He then used statistic calculations to develop a risk score that met this condition. 
This different approach might be a reason why electronic screenings often showed higher 
sensitivity values. The threshold when a sensitivity value is seen as sufficient or good has not 
been clearly determined in literature and depends on the subject of investigation. A screening 
tool for diagnostic use should show higher sensitivity and specificity values than a prognostic 
tool like the DART, which is intended to forecast the beneficial effect of targeted 
pharmaceutical activities. 
The following steps might have influenced our sensitivity and specificity values and have been 
examined more detailed in the discussion part of project B2:  
First the comprehensibility of the DART questions: Despite the fact that patients stated they 
understood the meaning of all questions in the DART, we discovered some problems with the 
understanding of the word “chronic”. In order not to bias our results we did not gave further 
explanations to the patient if we noticed some uncertainties. Some rephrasing of this word is 
recommended in order to clarify our statements. 
Second, the reliability of medical records and medication lists was sometimes questionable. 
Inaccurate medication lists could have been responsible for lower sensitivities when patients 
indicated the intake of different drugs, which were nonexistent in their patient charts. Data 
from the literature confirm the frequent incompleteness of medication histories in the 
hospital medical records [182, 183]. More reliable medication reconciliation will be necessary 
for further research, in order to avoid conclusions derived from incomplete medication data. 
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And third, successful implementation of patient self-assessment tools presumed reliable 
answers of the patients according to their illnesses and drug therapies. We observed that 
many patients showed poor knowledge about their disease state and they did not understand 
their drug therapy. Few patients wrongly confirmed the presence of a disease, whereas many 
patients erroneously denied any illnesses. These findings are consistent with an example from 
an Australian study [201] which did research on patients newly referred to a renal outpatient 
department and reported that these patients mostly received little or no education from their 
primary care physician and had poor or no knowledge about their kidney disease. A Danish 
study [202] evaluated the medication knowledge of elderly patients and revealed that only 
60% of the subjects knew the purpose of their medication. A small study from Norway [203] 
interviewed 58 patients from all age groups. Seven percent of the patients could not recall 
why their drugs had originally be prescribed. There is a need for a better patient education by 
all healthcare providers in primary and secondary care.  
In comparison with other self-assessment tools that we collected in the overview B3 [117, 157, 
159, 188, 191], the DART showed similar complexity regarding number of items with the 
advantage of an appealing and clearly structured design. The content of the tools appeared to 
be quite similar. The DART seemed to be very comprehensive and covered many RFs by asking 
patients about the presence of chronic diseases and polypharmacy, but also about physical 
disabilities, patient knowledge, adherence, as well as beliefs and concerns towards their 
medicines. Compared to Levy et al. [117] and Pit et al. [159] the DART did not target a specific 
patient group. Compared to the tools of Makowsky et al.[191], Rovers et al. [157] and Langford 
et al. [188] who focussed on primary care patients, the DART did not focus on a specific setting 
but has been developed in a secondary care setting. Together with the risk-assessment of Levy 
et al. [117], the DART tool appeared to be one of the best validated tool. However, a 
prospective validation regarding clinical outcomes is missing in the DART, as well as in all other 
self-assessment tools. 
In this thesis, we developed a first draft of the DART and proved its feasibility and acceptability. 
The validation of the reliability of patients’ answers resulted in a satisfactory specificity but a 
slightly low sensitivity. A rephrasing of some questions in the DART might enhance better 
understandability. A second validation with an accurate medication list and reliable medical 
data will be necessary to reevaluate sensitivity and specificity of the DART. The future aim of 
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our screening tool is the creation of a scoring system, in order to assign every patient a total 
score that identifies him for being a patient “at high risk” or “at low risk” for the development 
of DRPs. Then, a validation regarding the association between the DART score and the 
occurrence of DRPs is essential to prove the concept of our risk assessment.  
 
Limitations 
Project A: A limitation of project A was the applied search strategy. Different efforts to 
develop a systematic search strategy were undertaken. Unfortunately, the MESH term 
“Inappropriate prescribing” was introduced only in 2011 and prior to this included in the 
broadly defined MESH term “Drug therapy”. Using this MeSH-term revealed a large number 
of very diverse articles in the higher four-digit spectrum and made it impossible to screen and 
evaluate all titles and abstracts within the time scheduled for this work. However, despite the 
fact, that our search strategy did not fully correspond to a systematic review, we feel that our 
review has been the most comprehensive review on tools for the assessment of IP that has 
ever been published.  
Project B1: There were some general concerns about the validity and generalisability of 
information created by qualitative research methods. We discussed this fact in detail in the 
general introduction of project B and project B1. Results of the NGT could have been tampered 
by psychosocial influence of the NGT panellists as described by Pagliari et al [172]. The 
measures we initiated to keep these biases as small as possible were discussed in the general 
introduction of project B, in project B1 and in the final general discussion. A limitation of our 
Delphi technique might be the restricted number of participants, even if optimal size of 
panellists has not been established. Research has been published based on samples ranging 
from 4 to 3000 [76]. In addition, the results of the NGT, especially the discussion rounds, were 
confined to the Swiss health system and cannot be generalized to other countries. 
Project B2: A limitation of project B2 was the small patient sample. Precise conclusions to 
certain sensitivity and specificity values were sometimes not possible because of the very low 
prevalence of risk factors. For the selection of patients for the interviews, we screened patient 
charts for inclusion and exclusion criteria which could be assumed to have influenced our 
results (selection bias). In addition, the patients who agreed to the interview might have been 
those who generally show better knowledge of their disease and medicines. The patient 
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interview for the DART-validation were conducted by multiple investigators, resulting in a 
potential performance bias, despite a prior briefing of the investigators. The investigator (CK) 
who filled in the case report forms was not blinded to the patient answers in the DART, which 
could have potentially led to reader bias.  
Overview B3: The conducted literature search was not a systematic review, which could have 
led to the missing risk screening tool data. 
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Conclusions 
From the results and experiences of this thesis the following conclusions could be drawn: 
 Inappropriate prescribing (IP) is a major risk for the occurrence of DRPs. The avoidance of 
IP should not only be the task of the physician but shared between different healthcare 
providers in order to guarantee the most appropriate therapy. Tools for the assessment 
of IP can provide a useful aid to evaluate the appropriateness of a therapy, during a 
medication review, or during the process of prescribing itself.  
 Inappropriate prescribing assessment tools are numerous. They show a large variety in 
structure, degree of comprehensiveness and extend of validation. By providing an 
overview of published assessment tools, this thesis may assist healthcare providers to 
choose a tool, either for research purposes or for use in daily practice, according to the 
situation in which it is intended to be applied.  
 The Drug Associated Risk Tool (DART) is a promising approach for clinical pharmacists to 
assess patients at risk for the development of DRPs and thereby target their clinical 
pharmacy activities to those patients who benefit the most thereof. 
 The DART is based on a combination of a systematic literature search, with the 
professional experience and knowledge of a multidisciplinary expert panel, which enabled 
the comprehensive finding of risk factors for DRPs representing the real-life situation in 
the Swiss healthcare setting. 
 A first technical validation of the DART was successful and supported the concept of a 
patient self-assessment. Compared to similar self-assessment tools, the DART has 
comparable complexity and comprehensiveness, has an appealing design and shows a 
satisfactory validation concerning feasibility, acceptability and reliability of patients’ 
answers.  
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Outlook 
A first successful draft of the Drug Associated Risk Tool (DART) has been developed and 
validated. We saw a lower sensitivity of the DART compared to similar risk self-assessments. 
We proposed potential issues that might have affected the sensitivity of our tool: The 
understandability of the questions, the accuracy of medical histories and medical data and the 
reliability of patient answers.  
The following steps are recommended: 
1. A rephrasing of the statements with very low sensitivity values with the aim of improving 
the understanding of the question.  
2. A validation of the improved version of the DART concerning feasibility, acceptability and 
reliability of patients’ answers 
3. A validation in a more specific population could be considered in order to increase the 
prevalence of the risk factors.  
4. An accurate medication list is essential to avoid a falsification of validation results. 
5. After a second validation , there is a need for the development of a scoring system, in 
order to assign each patient a total score that characterizes him for being “ at high risk” 
or “at low risk” for the occurrence of DRPs 
6. A validation with clinical outcomes is crucial to prove the concept of the risk assessment. 
An association between a higher risk score and the occurrence of DRPs and adverse 
outcomes will be needed to justify the broad implementation of the DART. 
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